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Abstract 
Influenza infection remains constant threat to human health and results in huge financial loss 
annually. Rapid and accurate detection of influenza can aid health officials monitor influenza 
activity and take measurements when necessary. In addition, influenza detection in a timely 
manner can help doctors make diagnosis and provide effective treatment. Additionally, novel 
inhibitors of influenza virus are in high demand because circulating strains have started to 
develop resistance to currently available anti-viral drugs. 
Influenza virus has two surface glycoproteins: hemagglutinin (HA) and neuraminidase (NA), 
which play important roles in the influenza infection. The binding of HA to sialic acid-
containing carbohydrates on cell surface initiates virus internalization, while cleavage of 
terminal sialic acid by NA facilitates viral particle release.  In this dissertation, we focus on the 
development of glycan microarray that is comprised of a panel of NA resistant sialosides, and 
demonstrate the application of microarray to capture influenza virus at ambient temperature 
without the addition of NA inhibitors 
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1.1 Abbreviation  
Hemagglutinin; HA, Neuraminidase; NA, N,N Dimethyl formamide, DMF; Ethyl acetate, 
EtOAc; Trifluroacetic acid, TFA; Acetonitrile, CH3CN; Azidotrimethylsilane, TMSN3; 
Diethylamine DEA; Trimethylsilyltrifluoro methanesulfonate, TMSOTf; p-Toluene sulfonyl, Tos; 
Di-tert-butyl dicarbonate, (Boc)2O; tert-Butyl alcohol, t-BuOH; Methanesulfonyl chloride, MsCl; 
Methanol, MeOH; Tetrahydrofuran, THF; Dichloromethane, DCM; Hydrochloric acid, HCl; 
Triphenylphosphine, PPh3; Sodium sulfate, Na2SO4; Sodium azide, NaN3; N-methyl morpholine, 
NMM; 2-Chloro-4,6-DiMethoxy-1,3,5-Triazine, CDMT; Sodium methoxide, NaOMe; Cupric 
sulfate, CuSO4; Et3N: Triethylamine, TEA.  Azidotrimethylsilane, TMSN3; Tetrabutylammonium 
bisulfate, TBAB; p-Toluene sulfonyl, Tos; Di-tert-butyl dicarbonate, (Boc)2O; Methanesulfonyl 
chloride, MsCl. 
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Introduction 
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2.1 History of Influenza 
 Influenza is a respiratory illness that affects millions of people annually.  In addition to 
seasonal influenza, pandemics can cause considerable harm. The first major influenza pandemic 
was reported in 1918 (H1N1), also known as the Spanish flu, where approximately one third of 
the world’s population was infected, and deaths were estimated up to 50 million.1  After the 1918 
pandemic, there were no major pandemics for ~ 30 years.  In 1957, the Asian influenza (H2N2) 
outbreak led to 250,000 deaths in Hong Kong in a very short period of time.  The Asian 
influenza strain (H2N2) had a short life span and disappeared in only 11 years. 
 It is not until another decade later that another influenza pandemic infected a large 
number of people.  The outbreak of 1968 (H3N2) in Southeast Asia and migrated to Europe and 
the Americas.  This strain caused severe illness in the United States.  Nonetheless, in Western 
Europe, including United Kingdom, low death rates accompanied the severe illness.  It took 
another decade for the 1977 pandemic (H1N1) to arrive, but this strain was a juvenile age-
restricted strain.  The most recent pandemic occurred in 2009 (H1N1, swine flu).  The first 
reported case in the United States was reported in April 2009 and by June 2009, 18,000 new 
cases were reported.2  It is not until August of 2010 that the World Health Organization (WHO) 
declared an end to the H1N1 flu pandemic of 2009.  
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Table 1:  Deaths and infection rate associated with major pandemics. Table was adapted from 
multiple sources.2-3 
Table 1  Deaths and infections rate associated with major pandemics 
 
Pandemics Deaths Fatality Rate 
1918-1919 (H1N1) 20-100 million 2.0% 
1957-1958 (H2N2) 1-1.5 million 0.13% 
1968-1969 (H3N2) 0.75-1.0 million <0.1% 
2009-2010 (H1N1) 18,000-284,500 0.03% 
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Figure 1  Classification of the types of influenza virus. 
Figure 1:  Influenza is classified into three different types; A, B and C. 
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2.2 Classification of Influenza 
Influenza virus is classified into three types; A, B and C.  Types A and B are most 
important due to their ability to infects humans.  Type A influenza virus can be further broken 
into subtypes based on their two surface proteins; HA and NA. The virus was first isolated from 
swine in the late 1920s, followed by the first virus isolation from humans in 1933.4 Influenza 
type A is a member of the Orthomyxoviridae family and is characterized by the presence of eight 
segmented negative strand RNA.5  These single stranded RNA encoded for about 10 viral 
proteins.6  Amid the 8 single-stranded RNA, the two shortest are associated with nucleoproteins 
(NP) and all three P proteins (PB1, PB2 and PA).6  These proteins are viral machinery for RNA 
replications and transcriptions.  
Influenza virus (type A and B) contain three important surface proteins:  Hemagglutinin 
(HA), Neuraminidase (NA), and a M2 ion transporter. HA and NA are glycoproteins anchored 
on the lipid bilayers of the virus. They are very important in the replication process of the 
influenza virus.  Extensive research has shown that HA and NA binds to N-acetyl neuraminic 
acid (sialic acid) on glycoproteins and glycolipids of host cells.7  HA is implicated in the early 
stage of infection by recognizing the sialic residues on cell surface. This initial step is followed by 
endocytosis of viral particles into the cells.8 16 HA subtypes and nine NA subtypes that had been 
identified.9  These subtypes are conserved in type A influenza virus in aquatic birds 
population.5b, 9  Influenza type A, like many other viruses, goes through frequent evolutionary 
mutations at multiple levels.  These mutations is resulted from a number of mechanisms: point 
mutations (antigenic drift), gene re-assortment (genetic shift), defective interfering particles, 
and RNA recombinations.5b  Arise in drug resistant strains of influenza virus is the result of 
these frequent mutations.    
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Figure 2 Life cycle of the influenza virus 
Figure 2:  Life cycle of the influenza virus A.  Influenza A viruses composed of eight single 
stranded RNA and have three major proteins on the cells surfaces: HA, NA and M2 ion pumps.  
B. The influenza virus infection is initiated by the binding of HA to the host receptors which will 
induce endocytosis.  Once inside the cells, pH changes causes the fusion of viral envelope and 
endosome which will cause the release of vRNA.10  (Figure was taken with permission from 
publisher)  
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2.3 Life Cycle of Influenza 
 The cycle of influenza begins when HA binds to sialic acid, which is the cellular receptor.  
These sialic acids are the terminal carbohydrates bound to glycolipids or glycoproteins located 
on the cell surfaces.11  In humans, the infections begin in the upper respiratory track.   The 
binding leads to the fusion process to bring the viral particles into the endosome via 
endocytosis.12  M2 proteins responds to the low pH of the endosome by opening and allowing 
protons flux into the viral particles.12  The low pH causes the viral RNA to dissociate from the 
matrix proteins and the fusion of viral and endosome membranes.13  The fusion of viral and 
endosome results in the release of viral RNA into the cytoplasm.  When viral RNA is released, 
they must travel into the nucleus where they can replicate and transcribed into a positive sense 
RNA, which travel back into the cytoplasm to be translated into proteins.  Once the RNA has 
been replicated, the packaging and processing occurs and the viral progeny leaves the cell to 
infect other cells.  Influenza viruses leave the cells via a process call budding.  The influenza 
virus is an envelope virus, therefore, in the process of budding it uses the plasma membrane of 
the host cells to form its envelope.13  The surface of these newly formed viral particles contains 
all the required proteins to leave the host cells.  As the virus emerges, residual sialic acids on the 
dying mammalian cell bind to the viral progeny presenting the virus from infecting other cells. 
The virus overcomes this problem by using the surface glycoprotein, NA. The function of NA is 
to cleave terminal sialic acid from glycoproteins and glycolipids to release the newly formed viral 
particles to go and infect other cells.14 Details of the major influenza proteins are described in 
detail below.  
Influenza viral proteins  
There are a number of essential proteins important for the efficient replication of 
influenza viruses. We highlight the essential proteins.  
16 
 
 
 
2.4 Hemagglutinin (HA) 
HA is a receptor-binding glycoprotein that are composed of three identical subunits and 
is anchored on the surface of the influenza virus.8  HA proteins are classified into 16 different 
subtypes.15 Their roles are to recognize sialic acid present on the surface of host cells and to 
initiate the endocytosis process.  Sialic acid is conjugated to the 3 or 6 position of galactose 
present on glycolipids and glycoproteins. HAs from different viral strains prefer to bind to 
different oligosaccharides i.e. the nature of the penultimate saccharide and internal saccharides 
can dictate the binding preferences. For example, HA’s from the avian lineage prefers NeuAc α2, 
3 Gal linkages,15 while HA’s (H1, H2, and H3) from human lineage prefers NeuAcα2, 6-Gal 
linkages.16  On the other hand, HA’s from the swine lineage exhibits similar binding preferences 
to NeuAcα2, 3 Gal and NeuAcα2, 6 Gal linkages. 
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Figure 3  HA host transmission, homotrimer structure and receptors 
Figure 3: HA host transmission, homotrimer structure and receptors A) Schematic showing 
the relationship between HA’s from different lineage.  Avian HA’s prefers binding to NeuAcα2, 3 
Gal linked over NeuAcα2, 6 Gal linkages.  On the other hand, human HA’s preferred NeuAcα2, 6 
Gal linked over NeuAcα2, 3 Gal linkages.  Swine HA’s are able to recognize and bind to both 
substrates.14  B) Side and overhead view of the 1918’s H1 HA.  C) Receptors recognized by HA’s 
of different lineage. 
 
 2.5 Neuraminidase (NA) 
NA is the second major 
exist as tetramer that consist of four identical subunits with the molecular weight of 
approximately 240kD.17  The role of NA is to facilitate mobility of the influenza viruses’ particles.  
NA catalyzes the enzymatic cleavage of both NeuAα
cleavage of these terminal sialic acids gives several advanta
NA allows viral particles to move through mucin by cleaving sialic acid from host cells and 
preventing other influenza virus from infected already infected cells.  Second, NA can remove 
both sialic acid from cellular 
proteins.  Thus, NA prevents newly formed viruses from aggregating.  
 
Figure 
Figure 4:  Three dimensional structure 
B) Overhead view of a single unit of NA with binding site.
with permission) 
 
 
A 
 
surface glycoprotein of both influenza A and B viruses.  NA’s 
-2-3, and NeuAα 2-6 glycosidic bonds.  The 
ges to the replication
glycoproteins, glycolipids, and even from both virus surface 
 
4  Three dimensional structure of NA 
of Neuraminidase.  A)  Overhead view of NA tetramer.  
14 (Figure was taken Gamblin S.J. et al 
B 
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 cycle.   First, 
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NA is considered an exo-glycohydrolase; it hydrolyzes terminal sialic acid residues from 
glycoproteins and glycoconjugates.18  Cleavage of terminal sialic acids is initiated with the 
binding of to the active sites of NA.  The stable chair conformation is forced into a less stable 
boat conformer due to the highly conserved triarginyl cluster (Arg-118, Arg-292, and Arg-371).5b 
19  Conformational changes facilitate the departure of aglycon residue through the formation of 
an oxocarbocation ion intermediate (sialosyl cation).20  The sialosyl cation undergoes a 
nucleophilic attack to form a glycosyl-enzyme intermediate.  The glycosyl-enzyme intermediate 
breaks to form a sialosyl cation, where it goes under another stereo-selective nucleophilic attack 
by a water molecule to form an α-Neu5aAc as the first product to release for the active site.  The 
α-Neu5Ac product isomerizes into β-Neu5Ac, the more thermodynamically favored product. 
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Figure 5:  
Mechanism of Neuraminidase for cleaving terminal sialic acids.  Figure was adapt from Nature 
publisher with permission.7   
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Figure 5  Mechanism of NA for cleaving terminal sialic acid 
 2.6 M2 Proton Channel 
 M2 protein of type A and B influenza virus are homotetrameric, type III integral 
membrane proteins that are important to the life cycle of the influenza virus.
are responsible for the dissociation of the viral particles to release RNA materials.   At the later 
stage of replication, M2 is responsible for maintaining the high pH of the trans
prevent premature folding of HA.  M2 works a
mechanism. Researchers believe that the open and close mechanism is based on a single trans
membrane domain residue of tryptophan (Trp 
 
Figure 6  Three dimensional representation of tetrameric forms of M2 trans
Figure 6:  Three dimensional representation of the tetrameric forms of M2 trans
proteins.      A) Side view of the proteins 
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s a proton gate where they have an open and close 
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proteins. 
B) Overhead view of the proteins.24  
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2.7 Influenza Viral Polymerase 
 Influenza polymerase is a heterotrimer, which is composed of three subunits call PA, 
PB1, and PB2 with the molecular weight of approximately 250k Da.25  All three subunits are 
required for the transcription and replications of viral RNA.  Each unit has a distinct role in the 
transcription process.  The initiation step for viral RNA transcription is where the PB2 subunit 
recognizes cap structure of host pre-mRNA in the nucleus.26  The short capped oligomers (10-13 
nucleotides)27 is cleaved  by an endonuclease subunit of PA and is used to prime viral mRNA by 
the subunit of PB1.28  The transcription process ends when the polymerase recognizes the 
polyadenylation signal, a oglio-U sequence located near the 5’ end.26 Cusack et. al. was 
successful in obtaining X-ray crystals of the complete structure of influenza A and B polymerase 
including PA, PB1, PB2 and viral RNA promoter.29, 25  The crystal structure of both influenza A 
and B polymerase is expected to lead to potential therapeutics in the future.  
23 
 
 
 
Figure 7  Influenza viral RNA replication with polymerase 
Figure 7:  Influenza viral RNA replication with polymerase.  Polymerase composed of three 
subunits PB1, PB2 and PA.30  (Figure was taken with permission from Boivin S. et al) 
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2.7.1 Endonuclease (PA-Polymerase Acidic) 
 The role of PA unit in influenza polymerase was not well defined until recently. There are 
several clues that support PA with several roles in the transcription and replication processes.  
These roles range from endonuclease, protease activities, and cap binding.31  Recent publications 
have confirmed that the PA subunit main function is endonuclease.32  PA was cleaved into two 
subunits by proteolysis studies labeled as N-terminal (25-kDa) and C-terminal (55-kDa).30  The 
larger fragment is understood to be a binding site to PB1 during complex formations and serve 
as a nuclear transport.  The N-terminal domain is responsible for the cleavage of the CAP 
peptides from the host pre mRNA.30   
2.7.2 PB1-Polymerase Basic 1 
 Influenza polymerase has a very unique initiation step mechanism for viral RNA 
replication.  The combination of PA, PB1 and PB2 helps successfully “snack” the cap from 
cellular pre mRNA to prime its own RNA for replication.  In this process, PB1 has the most 
important role.33  It plays the central role in the RNA replication by acting as the backbone of the 
polymerase and holds the catalytic site for the RNA polymerase.33  PB1 has several highly 
conserve regions of amino acid (motifs I, II, III and IV) and they range from 4-13 amino acid 
residues.34  These highly conserved motifs participate in the active site of the polymerase. 
Cusack et al have reported the crystal structure for influenza A and B polymerase with all three 
subunits; PA, PB1 and PB2.29   
2.7.3 PB2-Polymerase Basic 2 
Polymerase Basic 2 serves as an initiator for vRNA transcriptions and replications.  It is 
also considered a major viral determinant for adaptation.  PA2 binds to host-cell pre-mRNAs via 
the 5’ cap (10-13 amino acid units) and is cleaved by the endonucleolytic activity of PA subunit.30  
The recognition of capped oligoribonucleotides by PB2 is stimulated by the binding of the 5’ end 
25 
 
 
of the viral RNA template to PB1 unit.35  The structure FluA PB2cap with 318-483 amino acid 
units containing cap-binding pocket complex with guinosine triphosphate (GTP) was recently 
determined. 36   Zheng et. al. has determined the structure for FluBcap with 318-484 amino acid 
units containing cap-binding pocket complex with guanosine diphosphate (GDP). 
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Figure 8  Three dimensional structure of influenza virus polymerase 
Figure 8:  Three dimensional structure of influenza virus polymerase.  Polymerase consists of 
three subunits PA, PB1 and PB2.  (Figure was taken from A. Pflug et al with permission). 29 
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2.8  Controlling the transmission of influenza viruses  
Influenza is a deadly pathogen and therefore, a number of methods have been employed 
to arrest the spread of this disease. These methods include proper hygiene, vaccinations, 
antivirals and rapid diagnostic tests for appropriate countermeasures. These different methods 
have been shown to arrest the spread of the disease, however as the virus has a high mutation 
rate, some of these methods are no longer effective. 
2.8.1 Vaccines  
 Influenza affects millions annually and thus the need for preventions are in high 
demand.  Antiviral drugs assist in treating the infected and also arrest the spread of the viruses.  
However, the excessive use of one kind of antiviral (Oseltamivir) has resulted in a number of 
resistant virus strains.37  Annual vaccinations against the influenza virus is a good method to 
control the spread.38  Vaccination generates antibodies that mainly targets HA surface 
glycoproteins.  As influenza antibodies mainly recognized specific regions on the globular head 
of the HA surface proteins, their efficiency relies on the similarities between the HA of the 
vaccines and the HA of the currently seasonal strains.  Recently, a trivalent influenza vaccine 
was produced that induced antibodies against H1 and H3 in human A virus and one single HA 
phylogentic lineage of influenza B virus.39  However, at the beginning of the 2013 influenza 
season, quadrivalent, live-attenuated (FluMist Quadrivalent, MedImmune) and inactivated 
(Fluarix Quadrivalent, GlaxoSmithKline, and Fluzone, Sanofi Pasteur) influenza vaccines were 
available. Despite these advances, there are problems.   It is not easy to predict the emergence of 
new variant strains for an upcoming season, which becomes problematic to produce vaccines 
and vaccinate millions in time for the new influenza season.38 There have been efforts to develop 
a “universal” vaccine for a broad spectrum of influenza strains and this effort remains an active 
area of research.  
28 
 
 
2.8.2 Current Anti-Influenza Drugs 
 A second method to control the spread of influenza and decrease the severity and time of 
illness, anti virals have been developed. These are given below.  
 
2.8.3 First Class of Anti-Influenza (M2 Inhibitors) 
 As mentioned above, the influenza virus particles have three major surface proteins.  
Among the three surface proteins, one is an ion channel (M2).  The M2 ion channel is 
responsible for transporting protons to facilitate dissociation of viral particle and the release of 
viral genome.40  This process is crucial for viral infections and therefore, was among one of the 
first proteins targeted for antiviral drugs.  The first class of antivirals that was used and most 
effective for the treatment of influenza are adamantane-based drugs.  Amantadine and 
ramantadine target M2 channel and were used as first-choice antiviral against outbreak of the 
influenza A virus.24  The antivirals work by direct pore-blocking mechanism.21  However, as the 
influenza virus mutate, these older antiviral drugs has proven ineffective.  Over 90% of the 
influenza viral A strains has shown resistance to this class of antivirals.  A more recent strain of 
H1N1 related to the 2009 pandemic outbreak, has also shown to be resistant to the adamantane-
based drugs.  Therefore, these drugs are no longer recommended in the treatment of influenza 
in the United States since 2005.41 
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Figure 9  Adamantane based antiviral drugs 
Figure 9:  Structures of adamantane based antiviral drugs used against the influenza virus.  
These class of inhibitors inhibit the M2 channel on the influenza virus. 
2.8.4 Second Class of Anti-Influenza (NA Inhibitors) 
 The next generation of antivirals that are more effective and less resistant drugs are 
inhibitors of NA. High resolution of X-ray crystallographic data have given insight into the 
active site of NA to develop two transition state analog inhibitors.  Zanamivir© is a sialic acid 
analog (2-deoxy-α-D-Nacetylneuraminc acid) that has a guanidine functionality at the 4th 
position of 2-deoxy-α-D-Nacetylneuraminc acid.  Oseltamivir© is a cyclohexene derivative that 
contains an amino functionality at the 4th position of the cyclohexene ring.   
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Figure 10  Structures of sialic acid and NA inhibitors 
Figure 10:  Structures of current NA inhibitors. A) Native sialic acid with numeric system for 
assigning carbon.  B)  Deoxy form of sialic acid with hydroxy group at the 4th position.  C)  
Zanamivir© is a deoxy form of sialic acid with a guanidine functional group at the 4th position.  
D)  Oseltamivir© derivative of clycohexane that mimics the transition state of sialic acid with an 
amino functional group on the 4th position.   
 Zanamivir and Oseltamivir both were approved by the FDA in 1999 and very few strains 
of virus has shown to be resistant.  Zanamivir is licensed under the trade name of Relenza is 
administered through an inhaler (10mg/dose) and Oseltamivir is licensed under Tamiflu.  
Oseltamivir is administered orally (75mg/dose).37 Oseltamivir is the more widely used in 
comparison to Zanamivir.  This is because of it’s good bioavailability as an oral drug and because 
most patients prefer oral medication over an inhaler.42 Unlike Ostelamivir, Zanamivir is 
administered by an inhaler device and must be administered twice a day for five days.  
Unfortunately, the more recent community outbreak in 2007-2008 of A(H1N1) has shown to 
have more Oseltamivir-resistant strains. Fortunately, most of the Osteltamivir-resistant strains 
are not resistant to Zanamivir. However, since patients prefer oral drugs and there is a strong 
possibility that resistance to Zanamivir may develop, there is an urgent need to develop better 
analogs.  
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Figure 11  Structure of Peramivir 
Figure 11:  Peramivir is a NA inhibitors recently approved by FDA for the treament of influenza 
in 2012. 
  With the demand for more effective drugs to combat the annual influenza outbreak and 
potential pademics, there are new drugs that were approved in 2012.  Peramivir (Rapiacta®, 
Peramiflu®, BioCryst Pharmaceuticals, Research Triangle Park, North Carolina, USA) is among 
one of the drugs that was in phase III clinical trials and was approved for used during the 2009 
H1N1 influenza outbreak under the Emergency Investigational New Drug (eIND) regulations.43  
Peramivir, unlike traditional NA inhibitors, it has a unique structure differ from known NA 
inhibitors.  This NA inhibitor exhibits high binding affinity that last up to 24 hours and has a 
slow dissociation rate.44 Premavir has been approved for the treatment of influenza in Japan and 
South Korea.43  Unlike Zanamivir and Oseltamivir, Peramivir is administered through IV with 
the dosage of approximately 12mg/kg.   
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Figure 12  Structure of Laninamivir and Laninaminvir octanoate 
Figure 12:  Laninaivir and its pro-drug structure.  The prodrug form has shown to have an half-
life of 41.4 hours in healthy adults. 
 Laninamivir, like Zanamivir, is administered through an inhaler and was approved for 
use in Japan in 2010.  Researchers have also developed a pro-drug form of Laninamivir by 
introducing an 8-carbon chain at the 9-position via an ester bond.  The pro-drug form of 
Laninamivir is currently under clinical trials and have shown to have a half-live of 
approximately 41.4 hours in mice.45  Other studies with healthy volunteers have demonstrated 
that Laninamivir pro-drug was slowly excreted from the body in a span of six days from one 
inhalation in healthy human volunteers.46  The long excretion time is due to the body 
hydrolyzing the long carbon chain to activate the pro-drug to its’ active form Laninamivir. 
2.9 Drugs in Clinical Trials.  
There are a number of influenza antivirals in clinical trials. We highlight some of the promising 
antivirals.  
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2.9.1 Fludase 
 DAS181 (Fludase® Ansun Biopharma Inc., San Diego, California, USA) is currently in 
clinical trials in the United States.  Fludase is composed of bacterial sialidase catalytic domain 
taken from Actinomyces viscous which is amphiregluin tag that is required for effective for 
targeting epithelial cells.47  The enzymatic mechanism of Fludase cleaves both α2,3- and α2,6- 
SA receptors on the host cells surface.  With the removal of these receptors, it renders the 
influenza virus entry into the cells.  Fludase is currently in phase II study and had shown to 
reduced viral load and significantly shorter time to reduced viral shedding.48  However, the use 
of Fludase has some concerns, one of which is systemic distribution and its effect on normal 
sialic acid function.   
2.9.2 Favipiravir 
 Favipiravir (T-705) is another class of anti-influenza drugs that is currently in clinical 
trials.  Unlike many anti-influenza drugs, Favipiravir mechanism of action works by inhibiting 
influenza viral RNA polymerase.  The anti-viral drug acts as a prodrug that is phosphor-
ribosylated in cells to the active form, favipiravir-RTP, which inhibits viral replications.  The 
active form of Favipiravir, Favipiravir-ribofranosyl-5’-triphosphate (RTP), acts as purine mimic 
and is incorporated into the nascent RNA strand and inhibits strand extension.49  Favipiravir 
have been shown to have effect on a range of types and subtypes of influenza including NA-
inhibitors resistant strains.50  Favipiravir is currently in stage II clinical trials in the United 
States and has been approved in Japan for pandemics.38   
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Figure 13  Structure of Favipiravir and how it is metabolized 
Figure 13:  Favipiravir is metabolized in the cells to first introduce a ribose sugar then it gets 
phosphorylated into the active form of the drug as an inhibitor against viral polymerase. 
2.9.3 Nitazoxanide and Tizoxanide 
 2-(acetyloxy)-N-(5-nitro-2-thiazolyl) benzamide or Nitazoxanide was first developed as 
an antiparasitic in the 1970s.  Later studies have shown that nitazoxanide is metabolized in the 
body to convert it into tizoxanide which have a range of threapeutic properties against a number 
of different diseases, such as:  influenza, Hepatitis B virus, Heptatisi C virus, human 
immunodeficiency virus (HIV) and even tuberculosis (TB).51  Nitazoxanide is the first class of 
antiviral drugs that has a broad spectrum of treatments for multiple diseases.  Therefore, it has 
been licensed in the United States for the treatment of intestinal infections.  Further, 
Nitazoxanide has been in clinical trials for the treatment of influenza.  In clinical trials, it has 
been shown to inhibit the replications of 16 strains of influenza A/H1N1, H3N2, N3N2, H3N8, 
H5N9, H7N1 and one strain of influenza B virus.  Studies have shown that nitazoxanide works 
by preventing the maturation of viral HA.51, 52, 53  Nitazoxanide is currently in phase III clinical 
trials and will be the largest clinical trial conducted for the treatment of acute uncomplicated 
influenza.51 
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Figure 14  Structure of Nitazoxanide and Tizoxamide 
Figure 14:  Structure of Nitazoxanide and its active form, Tizoxamide. 
2.9.4 Current Influenza Detection Methods 
 Early, rapid and accurate detection can also help in arresting the spread of influenza. 
There are several diagnostic tests for the accurate detection of influenza.  These techniques can 
range from viral isolations (most inexpensive), rapid diagnostic test kits (inexpensive but not 
accurate) and real-time reverse transcriptase polymerase chain reaction (RT-PCR) (expensive, 
highly accurate).  Although cell culture has been the golden standard for detection of respiratory 
virus, it requires a laboratory environment and takes days to confirm the infection.54  PCR has 
always been the most sensitive and most accurate method of detection, however, traditional 
PCR it required a long turnaround time and required highly trained technicians to operate.54 
Newer point of care PCR detection systems are faster, but requires expensive instrumentation 
and the right primers. Details of the different techniques are given below.  
2.9.5 Viral Isolation 
 Among all techniques used for the detection of the influenza virus, viral culture is 
considered the “gold standard” and is one of the most well established route.54  As the results of 
many clinical samples may have low virus titers and thus, amplification of viruses are required 
for accurate detection.  The amplification process can be done with a numbers of different cell 
lines; cell lines such as primary epithelial cells or human adenoid, Vero cells, MRC-5, primary 
monkey kidney cells and Madin-Darby canine kidney (MDCK) cells have been used for 
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amplification and isolation of influenza virus.  However, MDCK cells are most commonly used 
cell lines in the case of influenza virus is because it can support the growth of both influenza A 
and B.55  Traditionally, results of viral amplification can be observed based on cytopathic effect 
(CPE).  The concentration of viruses in a clinical samples are usually unknown and requires 
multiple passage before any CPE can be observed.  In order to determine if the sample is 
negative or not, it must has at least two passages and this can result in long turn overtime (can 
last up to 4-10 days).56  After viral culture, immunoassay can be done to characterize the 
viruses.56   
2.9.6 Polymerase Chain Reaction (PCR) 
 Polymerase Chain Reaction is a technique developed by Kary B Mullis in 1985 for the 
amplification of DNA materials.  This technique has been accepted as the gold standard for 
influenza virus detection because it is highly accurate and can differentiate the subtypes of 
influenza.57 58  However, PCR is limited due to the availability of primers for new emerging virus 
strains and also it requires specialized training.  In recent years, since the 2009 outbreak, the 
need for point of care detection kit has increase dramatically.  Due to the time constraint 
associated with traditional PCR, new emerging PCR based technology has emerged.59  These 
new technologies utilize the PCR based which are highly selective and highly accurate to detect 
influenza within four hours.  Currently, there are multiple PCR based assays that are approved 
by the FDA for the diagnostic of influenza.  The first of this class is Prodesse Proflu+ by Hologic 
which was approved by the FDA in 2008.60   
2.9.7 Rapid Diagnostic Tool (RDT) 
 The first detection method, enzyme immunoassays technology (EIA), was first approved 
by the FDA in 1970’s and followed by many more in the late 1990’s.  There are currently 16 Food 
and Drugs Administration (FDA) approved rapid diagnostic tool (RDT).  The basis for these 
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rapid diagnostic tools is antigen detection that target either the HA or NA of influenza.61  
However, many RDT’s exhibit poor sensitivities.61    
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Table 2: Compilations for the sensitivities of RDT's for the detection of influenza62(Table was 
taken from FDA website without permission)  
Table 2  Compilations for the sensitivities of RDT's for the detection of influenza 
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A (%) B (%)
Beckton Dickinson BD Veritor System for Flu A+B 9/7/2012 81.3 85.6
Beckton Dickinson BD Veritor System for Flu A+B 4/16/2012 83 81.3
Beckton Dickinson BD Veritor System for Flu A+B 10/28/2011 83.6 81.3
Quidel Sfia Influenza A+B FIA 10/24/2011 94.2 89.5
Alere Clearview Exact II 1/6/2011 94 77
Princeton BioMedtech BioSign Flu A+B 11/10/2010 92.6 86.6
Response Biomedical RAMP Influenza A/B 4/16/2008 80.2 76.2
Meridian True Flu 11/15/2007 86.6 60.2
Binax BinaxNOW Influenza A&B 11/9/2006 80.7 64.7
Genzyme Corp. OSOM Influenza A&B 2/21/2006 73.8 60
Beckton Dickinson Directigen EZ Flu A+B 7/7/2005 86.6 75.6
SA Scientific SAS FluAlert Influenza A & B 7/22/2004 76 90.5
Quidel Corp. QuickVue Influenza A + B Test 9/11/2003 80.5 70.1
Remel Xpect Influenza A/B 7/17/2003 92.2 97.8
Beckton Dickinson Directigen EZ Flu A+B 6/28/2000 86.2 82.4
Quidel Corp. QuickVue Influenza A/B 9/24/1999 74.8 NA
Manufacturer Devise Names Date of FDA Clearance
Sensitivity for
Influenza A & B
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2.9.8 Glycan based diagnostics  
 To overcome issues with current diagnostics, we have developed a receptor based 
approach for influenza viruses. Briefly, the virus requires HA and NA to bind to the cell surface 
sialic acids.  These two influenza glycoproteins are excellent targets for capturing influenza virus 
for use in diagnosis, particularly because there are approximately 200-300 copies of HA and 50-
100 copies of NA on a single viral particle, respectively. The same molecules can be used to 
inhibit the glycoproteins. Therefore, we developed sialic acid analogs as recognition molecules. 
The details of our approach, synthesis and biological studies are given in the following chapters.  
2.10 Summary 
Influenza virus affect millions worldwide annually.  It is well known that influenza 
viruses have several copies of HA and NA that are good targets for intervention.  The first class 
of antiviral is adamantane based, which block M2 protons pump proteins.  However, most 
strains of influenza viruses exhibit resistance to this class of antivirals.  The second generation of 
anti-viral for influenza are NA inhibitors. Oseltamivir, an orally available antiviral is widely 
used, but resistance to this antiviral is on the rise.  Thus, the need for newer drugs that exhibit 
less resistance is urgent.  We are developing sialic acid analogs that can be used to inhibit HA 
and NA. Our approach, design and synthesis are described in Chapter 3.  
Early detection of influenza viruses is also an important need to arrest the spread of this 
deadly disease.  However, detections methods currently on the market are inadequate because 
they are expensive, require trained personnel, equipment, or exhibit poor sensitivities.  The lack 
of good detection tests is problematic as most physicians prescribe antivirals based on 
symptoms. We have developed a receptor based method that uses sialic acid analogs to detect 
influenza viruses and determine drug susceptibility. The approach, synthesis and initial 
biological studies are described in Chapter 3.  
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3  
Glycan Based Detection and Drug 
Susceptibility of Influenza 
Viruses 
This work was published in ACS Analytical Chemistry 2014, 86, 8238-44.  A second manuscript is 
under preparation, 
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3.1 Abstract 
 Influenza viruses have three surface proteins, two of which are glycoproteins called HA 
and NA.  HA functions as an initiator for cellular infections by binding to highly specific ligands 
to gain entry into the cell. HA is known to bind to N-Acetyl neuraminic acid (NeuAc or sialic 
acid) conjugated to the 3 or 6 hydroxyl position of galactose. NA is an enzyme that facilitates the 
release of viral progeny that adheres to sialic acid of the dying cell. NA are known to cleave O-
linked sialic acid residues on both viral and non-viral glycoproteins. We have designed a panel of 
small molecules that can bind to these viral glycoproteins as recognition molecules to detect the 
influenza viruses.  These glycans were printed onto glass slides to evaluate their ability to 
capture the influenza viruses via NA.  We demonstrate that the glycans bind to three influenza 
viruses with high sensitivity. We also demonstrate drug susceptibility using FDA approved 
antivirals, Zanamivir and Oseltamivir.  Finally, we synthesized a novel molecule that can be used 
as a reporter molecule instead of antibodies as reporters.  
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3.2 Introduction  
 Influenza virus is a respiratory disease that causes 200,000 hospitalizations and over 
30,000 deaths in the United States annually.63  Pandemics, like the 1918 H1N1 “Spanish flu”, 
can cause millions of infections and deaths in addition to disruption of economic activity.64, 65  
Early detection is the key in arresting the spread of this disease, because most antivirals lose 
their efficacy if it is not administered within 24-48 hours upon infection.63  Thus, inexpensive 
point of care diagnostic devices that are capable of detecting the virus rapidly would be very 
useful to mitigate the effects of the virus and possibly arrest its spread.  One recent example 
where a rapid detection device was needed was the 2009 H1N1 “swine flu” pandemic.  The virus 
spread across the globe within ten days and resulted in an influx of patients at local clinics and 
hospitals. 66, 67, 68 This fast moving pandemic took the world by surprise and most medical 
facilities were overwhelmed.  There are a number of available methods for detecting influenza - 
polymerase chain reaction (PCR), antibody based tests and cell culture.  PCR based detection is 
the most accurate and definitive, however PCR is expensive and may require highly trained 
personnel to run samples.  Antibody based tests are the basis of all point of care diagnostic kits. 
These tests are can give results within 15-30 minutes, however, they are typically only used for 
surveillance due to their low sensitivity.69, 70  Cell culture traditionally has always been the 
golden standard for detecting respiratory diseases, however, it requires a long turnaround time 
and required trained personnel.  
 Influenza virus is known to bind to terminal residues of N-acetyl neuraminic acid (or 
sialic acid) of glycoproteins and glycolipids to induce cell entry. Thus, sialic acid can be used to 
capture influenza viruses as a receptor based approach.7, 71, 72  Glycan based receptors for 
diagnostics is a relatively new area of research.  Synthetically, glycans can be synthesized in 
large quantities with good economic yield. Glycans are highly robust under different conditions 
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and do not required refrigeration.72, 73, 74  Glycans are small molecules and are much smaller than 
antibodies or affibodies, therefore they can potentially be used in nanobiosensor applications, 
where a nano-glycan conjugate would not perturb the overall size of the nanoparticle.75  An 
added advantage with synthesized glycans is that we can introduce different functional groups to 
modify the glycans. A panel or library of glycans can be used to create a microarray, which can 
be used to study binding patterns of viruses.76, 77, 78  Indeed, other researchers have also 
developed glycan microarrays to capture influenza virus via HA using microarrays.  
3.2.1 Microarray Technology 
 Microarray technology has been around for several decades. Recently, this technology 
has been applied to study glycan-protein interactions.79, 80, 81, 82, 83, 84 Microarray technology has 
allowed researchers to investigate hundreds of glycan-binding proteins interactions on a single 
chip.81  Therefore, glycan microarrays are a good tool for the analysis of the specificity of ligands 
to influenza surface proteins.  It also has been shown to be a helpful tool for both intact viruses 
and recombinant HA.85 
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Figure 15  Microarray based assays platform 
Figure 15:  Microarray based assays have the ability to test the specificity of hundreds of 
glycan-binding protein interactions on a single strip.  Glycans can also be printed onto activated 
glass slides that will allow glycans to be molecularly attached onto the surface and to investigate 
the specificity of glycans to intact influenza virus and recombinant HA.85  (Figure was taken 
from Nature Publishing Group with permission).  
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Figure 16  Antibody based microarray assays as reporters 
Figure 16:  Microarray assays are traditionally done with antibodies as a tool for reporting the 
effectiveness of the assay.  However, there are some drawbacks when antibodies are used; first, 
they are hard to generate, second they are not stable if not stored at the proper conditions.   
(Figure taken from Nature Publishing Company with permission) 
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 Using microarray technology allows us to understand the fundamentals of virus-receptor 
relations; glycan microarray using O-sialosides have been used to explain the preference 
between 2,3 linkage and 2,6 linkage for different types of influenza viruses.86, 85, 87  However, one 
concern is that in order to use the same microarray with intact viruses is that NA cleaves O-
sialosides rapidly.88  Therefore, most published papers have performed assays at low 
temperature (4oC) and/or in the presence of NA inhibitors to avoid the NA from cleaving O-
sialosides.89, 90, 91  In order to overcome this issues, former lab members Dr. Yun He and Dr. 
Yang Yang designed and synthesized a panel of S-, N- or C-linked (Figure 16) that can be used 
to capture virus via HA at ambient temperature and without NA inhibitors. 
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Figure 17  First generation capture molecules 
Figure 17: First generation capture molecules (synthesized by Dr. Yun He and Dr. Yang Yang).  
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3.2.2 First Generation Capture Molecules 
Our first generation capture molecules were designed and synthesized by former lab 
members Dr. Yun He and Dr. Yang Yang.  These molecules are not susceptible to cleavage by NA 
as they do not have O-linkages7, therefore, they can be used with intact viruses.  The first 
generation capture molecules were able to capture influenza viruses based on our microarray 
assays and successfully generated a binding pattern for individual virus strains.  These 
molecules were tested against six influenza strains.  The results are shown below. The H1N1 
A/Puerto Rico/8/34 strain, for example, has higher affinity to compound SC6 rather than H1N1 
A/Brisbane/59/2007 that has a higher infinity to SC8.  In comparing the H1N1 A/New 
Caledonia/20/99 and H1N1 A/Solomon Islands/59/07, the binding patterns are not completely 
identical.  For H1N1 A/New Caledonia/20/99, compound SC3 and SC7 have a higher affinity in 
comparison to H1N1 A/Solomon Islands/59/99 where SC8 has the highest affinity.  In terms of 
the pandemic strains, H1N1 A/California/7/09, SC3, SC4 and SC8 have the highest affinity for 
this viral strain.  Based on these results, we can conclude that binding affinities for different 
ligands are completely different and a pattern of recognition can be potentially used to type the 
strain. 
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Figure 18  Binding profiles of different strains of influenza 
Figure 18:  Binding profiles of different strains of MDCK cell adapted influenza viruses.  
(Figure was taken from Dr. Yun He’s dissertation). 
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3.2.3 Second Generation Capture Molecules 
The second generation molecules were designed based on transition state analogs and 
the native sialic acid (SA).  These molecules were designed to target NA.  Based on the X-ray 
crystal structures, a number of NA inhibitors have been developed to mimic the transition state 
of the cleavage reaction.92, 19  These inhibitors are among some of the current anti-viral drugs on 
the market (Oseltamivir and Zanamivir).  The rational design is based on the crystal structure 
(Figure 19) where there are three amino acid residues in the active site interacting with the 
fourth position of SA, therefore, if a positively charge group, such as a guanidine group, is 
introduced the binding affinity will increase.7  Our design for this class of capture molecules was 
to introduce a linker to the 7 position of Zanamivir as modifications at this position do not affect 
the binding to NA. A second class of capture molecules were also developed. We introduced the 
guanidine or amino group at the fourth position to the native structure of sialic acid and we 
introduced a sulfur linkage (S-linked) at the second position.93 We also hypothesized that if we 
increase the number of ligands, the binding affinity will increase due the multivalency.94  Thus, 
we introduced a dimeric scaffold with two terminal alkyne functionalities that allow us to utilize 
azide-alkyne Huisgen 1,3-dipolar cycloaddition to attach the glycan monomers to the scaffold.  
The dimeric scaffold also helps in separating the glycan from the surface, giving it more mobility 
and accessibility to the NA.  
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Figure 19:  Active site of influenza NA. Figure was taken with permission from Nature 
Publisher.7 
 
 
 
 
 
 
 
 Figure 19  Active site of influenza NA 
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3.2.3.1 1,3 Huisgen Cycloaddition (Click-chemistry) 
Click-chemistry, also known as Huisgen 1,3-dipolar cycloaddition, involves an azido 
group reacting with an alkyne to form a five membered ring system.95  The reaction occurs due 
to the π electrons between the two systems, where it occurs in a concerted, pericyclic shift, 
therefore, it is considered a stereo conservative addition.  The stereo selectivity can be controlled 
using appropriate catalysts.  Thus, this type of chemistry is highly versatile and has broad range 
of applications.95, 96, 97  Click chemistry can also be used for our system, because we can use a 
copper (I) catalyzed reaction to selectively introduced our carbohydrate ligands onto the scaffold 
that is trans stereo specific.95   
 
 
 
 
 
 
 
54 
 
 
 
Figure 20  Click-chemistry selectivities 
Figure 20:  Cis and trans conformations for the formation of the triazole ring can be controlled 
with different catalysts. Trans-formation can be achieved with copper catalyst and Cis-
conformation can be controlled by ruthenium catalyst. 
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3.2.4 Synthesis of Second Generation Capture Molecules 
The structures of the eight molecules used in the development of our microarray based 
assays are shown in Figure 7.  There are several features of the designed molecules.  First, all 
eight molecules are derived from natural receptors (sialic acid).  Second, the molecules have a 
free amine at the end of the spacer, which is important for immobilizing it onto the glass slides 
that contains the activated carboxylic acid groups.  Third, the molecules also have an amine or 
guanidine group at the fourth position, thus this will result in high specificity binding to the 
influenza NA, that has been shown by crystal structures, but will not fit into human NA.  Fourth, 
we have designed two types of molecules; SC1-4 are sialic acid analogs that has a spacer 
attached to the second position via a thiol linkage, the other, SC5-SC8, are Zanamivir 
analogues that are attached to a spacer at the seventh position.  Finally, we recently have 
demonstrated that molecules similar to SC1-4 and bivalent molecules thereof, inhibited two 
H1N1 and H3N2 strains at low nanomolar concentrations, here we designed monovalent and 
divalent derivatives.93  We have designed a divalent scaffold for two reasons; first, the divalent 
scaffold provides additional distance from the microarray surface for viral NAs’ to bind.  Second, 
NA exist in tetramer with four binding sites from one single NA tetramer or, fit into the pockets 
of two adjacent NA tetramers on a single viral particle.  When these mono and divalent 
molecules are tethered on a surface, the overall binding affinity of multiple glycans with the 
influenza viruses are expected to increase exponentially.   
 The synthesis of the molecules is shown in Scheme 1.  For SC1-4, the synthesis begins 
with commercially available sialic acid from Carbosynth and is esterified by suspending 
compound 1 in MeOH and the pH was adjusted with DowX H+ resin to 2, then allowed to stir 
overnight to yield compound 2 in quantitative yield.  Compound 2 was then subjected to acetic 
anhydride in pyridine to convert the free hydroxyl groups into acetate groups with quantitative 
yield to give compound 3.  An azido group was introduced at the fourth position by a two-step 
one pot synthesis starting with compound 3 in anhydrous EtOAc and TMSOTf at 40oC for hour 
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hour, then after work up and being dried, it was dissolved in t-BuOH and TMSN3 was refluxed 
overnight to yield compound 4 with an overall yield of 90%.  Compound 6 was made by 
dissolving compound 4 in CH3CN with LiCl and HCl gas was bubbled through for five days and 
neutralized to give compound 5.  Compound 5 was dissolved in a DCM:H2O system with TBAB 
and KSAc which was allowed to stir overnight to yield compound 6.  Compound 7 was 
synthesized by reacting compound 6 with 6-chlorohexyl 4-methylbenzenesulfonate in 
anhydrous DMF and TEA to yield 7 in 90% yield.  With compound 7 in hand, the reduction of 
compound 7 with triphenyl phosphine in THF:H2O (1:1) system and the amine was protected 
with di-t-butyl carbonate anhydride and TEA in THF resulted in 85% yield of compound 8a.  
Compound 8b was made in a similar fashion, where compound 7 was reduced and reacted with 
1,3-bis(tert-butoxy-carbonyl)-2-methyl-2-thiopeseudourea, HgCl and TEA in anhydrous DCM 
with 85% yield.  Compound 9a and 10b were made in similar fashion; compound 7a or 7b was 
dissolved in DMF, then NaN3 was added and heated at 60oC to give 95% and 96% yield, 
respectively.  Zemplén deprotection to remove the acetates and methyl ester was followed by 
acidic removal of the tert-butoxy groups and reduction of the azide using hydrogenation 
conditions yielded the monovalent compounds SC1 and SC2 which had an amine and a 
guanidine group at the four position of the sialic acid, respectively, from compound 8a,b.  The 
key intermediate compounds are 8a and 8b, because they can be “clicked” to our divalent 
scaffold.  Copper(I) catalyzed 1,3 dipolar addition of 8a,b with a dimeric scaffold, 10 bearing 
two alkyne groups yielded the fully protected divalent compounds, 10a,b in good yields. 
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Figure 21  Structure of synthesized molecules 
Figure 21: Structures of synthesized molecules for the capture of influenza viruses. Figure 
taken from Analytical Chemistry with permission.98 
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Figure 22:  a) Dowex H+ Resin, MeOH.  b) Acetic anhydride, pyridine.  c) i. TMSOTf, EtOAc, 
40oC, 4h, ii.  TMSN3, t-BuOH, reflux. d) LiCl, HCl(g) CH3CN.  e) KSAc, TBAHS, DCM:H2O.  f) 6-
chlorohexyl 4-methylbenzenesulfonate, TEA, DMF. g) i. Ph3P, THF:H2O, ii. 1,3-Bis-(ter-
butoxycarbonyl)-2-mehtyl-2-thiopseudoharnstoff, HgCl, TEA, DCM.  h) i. Ph3P TFH:H2O, ii. di-
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t-butyl carbonate anhydride, TEA, THF.  i) NaN3, DMF.  j) i. NaOMe, MeOH  ii. 50mM NaOH 
iii. TFA:DCM.  k) Sodium ascorbate, CuSO4, THF:H2O (1:1).  
The synthesis of SC5-8 was done by Xiaohu Zhang and is shown in Scheme 2.  
Compound 4 was taken and the azido group was reduced via hydrogenation with Lindlar 
catalyst in EtOH to give compound 10 with quantitative yield.  Compound 10 was subjected to 
based induced deprotection of the acetate groups and acetonide protection of the 8,9 hydroxyl 
groups leaving the 7 hydroxyl group open for conjugation to the spacer.  Compound 12 was 
obtained by converting the free hydroxyl group at the 7th position of compound 11 into an 
activated ester via 4-nitrophenyl chloroformate with DMAP and pyridine.  The active ester was 
then reacted with 7-azidoheptan-1-amine in THF and TEA to yield compound 12 with the yield 
of 89%.  The acetonide group was removed under mild acidic conditions to produce 13a.  The 
guanidine derivative was synthesized from compound 13a, the tert butoxy group was removed 
and a suitably protected guanidine group was attached to the free amine to yield 13b in 
significant amounts.  This strategy of installing the guanidine group at this later stage was more 
successful in our hands as opposed to introducing the guanidine group early in the synthesis, the 
latter gave us undesirable products and variable results. Global deprotection of 13a,b was 
performed as described for SC1,2 to yield SC5,6 in good yields.  The final compounds were 
purified using size exclusion chromatography using Biogel P2 and the appropriate fractions 
containing the compounds were freeze dried to produce colorless foamy material.   
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Figure 22  Synthesis scheme of Zanamivir analogs 
Figure 23:  l) Lindlar Catalyst, H2, quantitative yield  m) i. NaOMe, MeOH, quantitative yield 
ii. H+ resin, acetone, 12 h, 88%.  n) i. 4-nitrophenyl chloroformate, DMAP, pyridine, 80% yield, 
ii. 7-azidoheptan-1-amine, TEA, THF, 89% yield. o) i. TFA:DCM (1:1), ii. 1,3-Bis-(ter-
butoxycarbonyl)-2-mehtyl-2-thiopseudoharnstoff, HgCl, TEA, DCM, 84% for 14b.  j) i. NaOH 
50mM ii. TFA:DCM (1:1) quantitative yield.  k) Na-Lascorbate, Copper sulfate. THF/H2O, 12h, 
78% for 16a; 80% for 16b. (Work was done by Xiaohu Zhang) 
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3.3 Alternative to Antibody-Based Reporting Microarrays 
As reported earlier, we have developed a number of bivalent sialic acid scaffolds that 
have the ability to capture the influenza virus via NA; SC3, SC4, SC7, SC8.  We have utilized 
the same scaffold with the same substrate, and we have installed a biotin handle at the free 
primary amine that is located on the spacer (Figure 23).  The biotin handle will allow us to use 
labeled streptavidin as a reporter.  Biotin-streptavidin dissociation constant (Kd) is extremely 
low, and there have been many applications designed using this concept.99  Furthermore, 
streptavidin is highly stable that exists in a homo-tetrameric form and thus, multiple 
biotinylated compounds can bind to streptavidin increasing the multivalency.100  Taken 
together, the stability, multivalency, and low Kd, allow biotin-streptavidin to be used as a handle 
for highly specific detection.   
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Figure 23  Synthesized biotinylated reporter molecules 
Figure 24:  SC3, SC4, SC7, SC8 were used and we introduced a biotin handle to allow us to 
use fluorescently labeled streptavidin as a reporting method.  
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3.3.1 Biotin-Streptavidin  
 The protein, streptavidin, was first discovered to cause nutritional deficiency in rats due 
to the formation of a highly water soluble, non-covalent complex with biotin (vitamin B7).99  The 
affinity between biotin-streptavidin is exceptionally high (Kd = 10-15 M) and therefore has very 
specific binding.  Streptavidin exists in a tetrameric form with four identical subunits with a 
molecular weight of 52.8 KDa.99  The crystal structure was first reported in 1989 by two 
independent groups.   Biotin-streptavidin interaction have been applied to numerous assays 
such as enzyme linked immunosorbent assay (ELISA), immunohistochemistry (IHC), Western, 
Northern, and Southern blotting, immune precipitation, cell-surface labeling, affinity 
purification, fluorescence-activated cell sorting (FACS) and electromobility shift assays 
(EMSA).99 
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Figure 24  Three dimensional structure of streptavidin 
Figure 25:  Three dimensional structure of Streptavidin.  Streptavidin exists as a tetramer with 
four identical subunits.  Biotin-streptavidin binding affinity has one of the highest interactions 
known in biological systems.  Structure was taken from Pugliese, L. et al with permission.100 
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Figure 25  Microarray assays designed with labeled streptavidin 
Figure 26:  Schematic of our assay; we will be immobilizing our glycans on glass slides, 
described in a previous chapter, and will use biotinylated compounds coupled with labeled 
streptavidin as a method for quantifying our results. 
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Figure 26  Synthesis of biotinylated S-linked sialic acid 
Figure 27:  a) i. DCM:TFA, ii) 7-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)heptanoic acid, 
CDMT, NMM, THF 80%.  b) i. DMF:Piperidine, ii. (+)-Biotin N-hydroxysuccinimide ester, TEA, 
DMF 62% over two steps.  c) Sodium ascorbate, CuSO4, THF:H2O:t-BuOH (1:1:1) 60-65%.  d) i. 
NaOMe, MeOH, ii. NaOH (50mM), iii. DCM:TFA (1:1) 70-75%. 
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Dimeric scaffold 17 was first subjected to acidic removal of the tert-butoxy groups 
yielding the intermediate amine.  The amine was then react with known 7-aminoheptanoic acid 
(NH-Fmoc protected) by CDMT-NMM coupling condition to give compound 18 with high yield.  
Fmoc protecting group were used because we want to be able to selectively deprotect this amino 
group to react with an activated biotin compound.  Compound 18 was subjected to Fmoc 
deprotection in pyperidine and DMF system (1:1) to yield an amine intermediate.  The amine 
intermediate is then reacted with (+)-Biotin N-hdroxysuccinimide ester in DMF and TEA to 
yield compound 19 in quantitative yield.  Copper(I) catalyzed 1,3 dipolar addition of 8a,b with a 
dimeric scaffold, 19 bearing two alkyne groups yielded the fully protected divalent compounds, 
20a,b in good yields.  Zemplén deprotection to remove the acetates and methyl ester was 
followed by acidic removal of the tert-butoxy groups yielded the divalent compounds SAR and 
SGR. 
3.4 Biological Assays  
 All final compounds were printed onto commercially available glass slides with activated 
carboxyl groups for the conjugation of the free amine from SC1-8 to produce a microarray.  
Microarray printing was done with various concentrations; the optimized concentration of 200 
µM for all assays gave the best signal to noise ratio.  We printed amine terminal PEG as a 
negative control.  The microarray assay was done using three different influenza strains; two 
H1N1 A/Brisbane/59/2007 & A/Solomon Island/3/2006 and an H3N2 strain 
A/Aichi/2/1968H3N2.  The strains were incubated at room temperature for 1h to allow 
attachment of viral particles to printed compounds, followed by incubation of the appropriate 
primary and fluorescently labeled secondary antibody.  The slides were washed at every stage 
extensively before scanning. The slides were scanned with Genepix scanner at 532 or 635 nm.  
Fluorescence image is reproduced in Figure 14 where the printed compounds were exposed to 
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105 PFU/ml (plaque forming units) of H1N1 Influenza virus A/Brisbane/59/2007.  As seen in 
the figure, bivalent compounds, SC3,4,7,8 capture the virus very well.  However, almost all the 
monovalent compounds, SC1,2,5,6 have weak binding to this strains, suggesting there should 
be a minimal distances between the glass surfaces and the glycans for sufficient binding to 
occur.  The same compounds were assays against an H3N2 (A/Aichi/2/1968) strain shows 
similar results, however when assayed against H1N1 (A/Solomon Island/3/2006) all 
compounds show excellent binding.  We also observed differentiation of the binding patterns for 
these compounds to different strains of influenza viruses.  For example, A/Aichi/2/1968 strain 
exhibits similar binding patterns for all bivalent compounds, whereas A/Brisbane/59/2007 
strain binds better to the bivalent compounds SC4 and SC8.  Compounds SC4 and SC8 are 
compounds that have a guanidine groups at the 4th position and the best binding is SC4.  Next, 
we determined the analytical sensitivities of our microarray assays using different 
concentrations of the different strains from 106 to 101 PFU/ml.  Figure 15 shows all bivalent 
compounds, SC3,4,7,8, bind well at higher concentration of viral particles according to 
fluorescence intensities.  Further, at low concentration, 101 PFU/ml, all bivalent compounds 
bind H1N1 A/Brisbane/59/2007 and A/Solomon Island/3/2006, however only SC3 binds to the 
H3N2 A/Aichi/2/1968 strains at this concentration.  Finally, we tested the microarray for 
susceptibility to FDA approved antivirals, Zanamivir and Oseltamivir (Figure 7).  We first 
premixed each of the three strains of viruses with either one of the antivirals and exposed this 
mixture to the microarray.  After sufficient washing we detect using the appropriate primary 
antibodies and subsequent secondary antibodies.  The results supported our hypothesis.  When 
we introduced NA inhibitors they blocked the binding sites, which leads to no signal.  However, 
among our eight compounds, there are two outliers SC3 and SC7.  In the presence of antivirals, 
SC3 binds to H3N2 A/Aichi2/1968 strains and SC7 binds to both H1N1 strains.  Presumably, 
these molecules have some binding affinity to HA and therefore were able to capture some viral 
particles.   
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Figure 27  Influenza binding studies 
Figure 28:  Influenza binding studies A. Fluorescence image of microarray containing eight 
glycans (SC1-SC8) after exposure to 105  PFU/ml of H1N1 Influenza A/Brisbane/59/2007, 
followed by  ferret hyperimmune sera and anti-ferret rhodamine labeled secondary antibody for 
A/Brisbane/59/2007 and scanned by Genepix scanner at 532 nm.  B.  Fluorescence detection of 
two H1N1 (A/Brisbane/59/2007 and A/Solomon Islands/3/2006) and one H3N2 
(A/Aichi/2/1968) influenza A viruses using synthetic glycans.  Glycans, PEG (negative control) 
and biotin (positive control) were printed at 200µM. All virus concentrations were 106 plaque 
forming units (PFU). Fluorescence intensity was measured by the Genepix scanner using ferret 
hyperimmune sera to influenza A/Brisbane/59/2007 (H1N1) and anti-ferret rhodamine labeled 
antibody; ferret hyperimmune sera to influenza A/Solomon Islands/3/2006 (H1N1), and anti-
ferret rhodamine labeled antibody; polyclonal antiserum chicken to A/Aichi/2/1968 (H3N2), 
and Alexa Fluor® 633 labeled anti-chicken. A/Brisbane/59/2007 and A/Solomon 
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Islands/3/2006 were scanned at 532nm and A/Aichi/2/1968 at 635nm. All experiments were 
performed in triplicate.  (Experiments were done by Joyce Sweeney).  
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Figure 28  Analytical studies using synthesized molecules 
Figure 29:  Analytical studies. A. H1N1 Influenza A/Brisbane/59/2007. B. H1N1 Influenza 
A/Solomon Islands/3/2006. C. H3N2 Influenza A/Aichi/2/1968. Fluorescence intensity was 
measured as previously described for figure 14. All experiments were performed in triplicate. 
(Experiments performed by Joyce Sweeney).  
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Figure 29  Drug susceptibility test using synthesized molecules 
Figure 30: Drug susceptibility test. A. H1N1 Influenza A/Brisbane/59/2007. B. H1N1 
Influenza A/Solomon Islands/3/2006. C. H3N2 Influenza A/Aichi/2/1968. 10 ng of antivirals 
Zanamivir® or Oseltamivir® were premixed with the strains at 105 PFU for 30 min at rt and 
subsequently added to the microarray. Fluorescence intensity was measured as previously 
described for figure 14. All experiments were performed in triplicate. (Experiments performed 
by Joyce Sweeney).  
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3.5 Summary  
We have successfully synthesized eight glycans, printed them onto glass slides and 
demonstrated their ability to capture three influenza strains at different concentrations.  
Through the microarray assays, we have determined limit of detection for our platform to be 1o1 
PFU, which is extremely low in terms of sensitivity.  We have also performed drug susceptibility 
on the FDA approved antivirals, Zanamivir and Oseltamivir, by premixing the antiviral with the 
viruses and then performing the assays.  Therefore, our platform can rapidly be performed 
within hours using minimal instruments.  Our microarray assays detection platform has several 
advantages over traditional methodologies, where our platform does not required highly trained 
personnel, specialized equipment and long turnaround times.  We are currently developing 
second generation capture molecules where they can bind to more strains.  Optimization of 
these molecules, testing different conditions and biosensor platforms. This assay has the 
potential to be translated to a rapid diagnostic test.  
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3.6 Chemical synthesis and characterization 
6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy -Dglycero-α-D-galacto-
non-2-ulopyranosyl) onate]-1-chloro-hexane 
 
 To a stirring solution of compound 1 (500 mg, 0.94 mmol) was dissolved in DMF (1.0 
mL) and TEA (0.95, 9.4 mmol) was added.  The mixture was allowed to stir for 10 minutes then 
6-chlorohexyl 4-methylbenzenesulfonate (350.0 mg, 1.1 mmol) was added and the reaction was 
allowed to stir overnight.  The reaction mixture was poured into a brine solution and extracted 
with ethyl acetate (3x).  Organic layers were combed and washed with HCl solution (1M, 1x).  
The organic layer was dried over sodium sulfate and concentrate on vacuo.  Compound was 
purified via column chromatography with hexane and acetone (3:1 ratio) as eluent to yield 
yellow oil (80% yield).  1H-NMR (400 MHz, CDCl3) δ ppm  5.57 (d, J = 8 Hz, 1H), 5.39-5.36 (m, 
1H), 5.31 (d, J = 7.6 Hz, 1H), 4.34-4.30 (m, 1H), 4.25-4.19 (m, 1H), 4.11 (d, J = 10.8 Hz, 1H), 
4.06-4.02 (m, 1H), 3.83 (s, 3H), 3.56 (t, J = 6.4, 13.2 Hz, 2H), 3.33-3.25 (m, 1H), 2.82-2.73 (m, 
2H), 2.59-2.53 (m, 1H), 2.18 (d, J = 3.2 Hz, 6H), 2.06 (s, 3H), 2.01 (s, 3H), 1.81-1.73 (m, 3H), 
1.546-1.39 (m, 6H).  13C-NMR (100 MHz, CDCl3) δ ppm 170.8, 170.7, 170.6, 170.0, 168.3, 82.9, 
72.8, 68.3, 68.0, 62.0, 58.0, 52.3, 45.0, 38.2, 32.4, 29.1, 28.7, 28.0, 26.3, 23.45, 21.1, 21.0, 20.7.  
HRMS (ESI):  Calculated for; C24H37ClN4O10S 608.1919, found; 609.1975 (M+H). 
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6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy -4-(N-tert-butyloxycarbonyl)-
amino-D-glycero-α-D-galacto-non-2-ulopyranosyl)onate]-1-azidohexane 
 
 To a stirring solution of compound 2 (0.20 g, 0.33 mmol) in a mixture of THF: H2O (5.0 
ml, 1:1), PPh3 (0.10 g, 0.39 mmol) was added and the reaction was heated at 40 °C for 12 h. The 
solvent was removed in vacuo and the residue purified by column chromatography to obtain a 
clear oil. This compound was directly taken to the next step without further purification. To a 
stirring solution of the crude product (0.18 g, 0.31 mmol) in THF (0.010 L) and TEA (31 mg, 
0.31 mmol), di-t-butyl carbonate anhydride (0.10 g, 0.47 mmol) was added. Reaction mixture 
was stirred for 12h at rt. The white solid was filtered and the residue was concentrated, dissolved 
in DCM (25 ml) and washed with HCl (25 ml, 1M, 1x). The organic layer was dried over Na2SO4 
and concentrated in vacuo. Product was purified via column chromatography with hexane: 
acetone (5:1) to yield a clear yellow oil (0.13 g, 60% yield over two steps). 1H NMR (400 MHz, 
CDCl3) δ 5.46 (s, 1H), 5.33 (s, 2H), 4.75 (d, J = 8.8 Hz, 1H), 4.28 (d, J = 12 Hz, 1H), 4.09 (d, J = 
8.8 Hz, 1H), 3.88 (d, J = 10.4 Hz, 1H), 3.79-3.73 (m, 5H), 3.52 (t, J = 6.4, 3H), 2.72 (d, J = 11.6 
Hz, 2H), 2.54-2.48 (m, 1H), 2.15 (s, 3H), 2.11 (s, 3H), S-4 2.03 (s, 3H), 1.88 (s, 4H), 1.77-1.71 (m, 
4H), 1.38 (s, 19H). 13C NMR (100 MHz, CDCl3) δ 171.0, 170.7, 170.0 169.9, 168.7, 156.0, 83.4, 
80.0, 68.5, 67.5, 62.2, 52.9, 50.2, 50.0, 45.0, 39.2, 32.4, 29.1, 28.7, 28.3, 26.4, 23.2, 21.2, 20.8, 
20.7. HRMS (ESI): Calculated for C29H47ClN2O12S: 682.2538; Found: 683.2613 (M+H). 
To a stirring solution of the chloro derivative (71 mg, 0.10 mmol) in DMF (1.0 ml) NaN3 
(65 mg, 1.04 mmol) was added and stirred at 60 °C. After 12 hr, the reaction mixture was 
quenched with DI water (25 ml) and extracted with DCM (25 ml, 3x). The organic layers were 
collected and washed with brine (25 ml, 1x), dried over Na2SO4 and concentrated in vacuo, to 
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yield a clear oil (64 mg, 90% yield). 1H NMR (400 MHz, CDCl3) δ 5.47 (d, J = 12 Hz, 1H), 5.33 
(s, 2H), 4.75 (d, J = 8 Hz, 1H), 4.29 (d, J = 12 Hz, 1H), 4.09 (d, J = 8 Hz, 1H), 3.87 (m, 1H), 3.79 
(s, 3H), 3.60 (m, 1H), 3.52 (vt, J = 12, 8.0 Hz, 2H), 2.73 (d, J = 12 Hz, 2H), 2.54-2.48 (m, 1H), 
2.15 (s, 3H), 2.11 (s, 3H), 2.03 (s, 3H), 1.88 (s, 3H), 1.77-1.74 (m, 3H), 1.5-1.40 (m, 2H), 1.38 (s, 
14H). 13C NMR (100 MHz, CDCl3) δ 171.0, 170.7, 170.1, 170.0, 168.7, 156.0, 83.4, 80.0, 68.5, 
67.4, 62.2, 52.9, 50.2, 50.0, 45.0 39.2, 32.4, 28.3, 26.4, 23.2, 21.2, 20.84, 20.80. HRMS (ESI): 
Calculated for C29H47N5O12S: 689.2942; Found: 690.3004 (M+H). 
 
6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl)onate]-hexane 
 
To a stirring solution of compound 2 (0.11 g, 0.20 mmol) in a mixture of THF and H2O 
(2.0 ml, 1:1), PPh3 (62 mg, 0.24 mmol) was added and heated at 40 °C for 12 hr. The solvent was 
removed in vacuo and purified by column chromatography using DCM:MeOH (10:1) and used in 
the next step without purification. This compound (0.10 g, 0.16 mmol) in DCM (0.01 L), TEA 
(0.3ml, 1.6 mmol) was added and stirred for 10 min at rt. 1,3-bis(tert-butoxy-carbonyl)-2-
methyl-2-thiopseudourea (55 mg, 0.19 mmol) and HgCl2 (51 S-5 mg, 0.19 mmol) was added and 
stirred for 12 h. Next, the reaction mixture was washed with H2O (25 ml, 1x) and brine (25 ml, 
1x). The organic layers were separated, dried over Na2SO4 and concentrated in vacuo. Product 
was purified using column chromatography with hexane:acetone (3:1 ratio) to yield a clear oil 
(0.12 g, 80% yield). 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 1H), 8.35 (d, J = 8.0 Hz, 1H), 6.05 
(d, J = 8.0 Hz, 1H), 5.37-5.29 (m, 2H), 4.36-4.33 (m, 1H), 4.06 (s, 3H), 3.54 (t, J = 12, 4.0 Hz, 
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2H), 2.82-2.74 (m, 2H), 2.56-2.53 (m, 1H), 2.17 (s, 3H), 2.14 (s, 3H), 2.04 (s, 3H), 1.83 (s, 4H), 
1.48 (s, 24H). 13C NMR (100 MHz, CDCl3) δ 170.8, 170.7, 170.2, 170.1, 168.8, 163.0, 156.8, 
152.7, 83.8, 83.3, 79.5, 75.4, 69.0, 67.8, 62.4, 52.9, 50.5, 49.7, 45.0, 38.8, 32.4, 29.1, 28.7, 28.3, 
28.0, 27.9, 26.4, 23.0, 21.2, 21.0, 20.8. HRMS (ESI): Calculated for C35H57ClN4O14S: 
824.3281; Found: 825.3348 (M+H).  
To a stirring solution of the chloro compound (47 mg, 0.06 mmol) in DMF (1.0 ml), 
NaN3 (39 mg, 0.60 mmol) was added and stirred at 60 0C. After 12 h, the reaction mixture was 
quenched with H2O and extracted with DCM (25 ml, 3x). The organic layers were collected and 
washed with brine (25 ml, 1x), dried over Na2SO4 and concentrated in vacuo, to yield a clear oil 
(40 mg, 85% yield). 1H NMR (400 MHz, CDCl3) δ 11.31 (s, 1H), 8.40 (d, J = 7.0 Hz, 1H), 6.03 
(d, J = 8.7 Hz, 1H), 5.33 (t, J = 15.6 Hz, 4H), 4.35 (d, J = 12.4 Hz, 2H), 4.14 – 3.94 (m, 4H), 3.91 
– 3.69 (m, 7H), 3.27 (t, J = 6.8 Hz, 4H), 2.99 – 2.47 (m, 9H), 2.17 (s, 5H), 2.15 (s, 5H), 2.05 (s, 
6H), 1.84 (s, 5H), 1.60 (d, J = 6.3 Hz, 6H), 1.49 (s, 22H), 1.39 (s, 10H), 1.26 (s, 8H). 13C NMR 
(100 MHz, CDCl3) δ 170.8, 170.6, 170.2, 170.1, 168.8, 162.9, 156.8, 152.7, 83.8, 83.3, 79.5, 77.3, 
77.0, 76.7, 75.4, 69.0, 67.8, 62.4, 52.9, 51.3, 50.4, 49.7, 38.8, 29.7, 29.1, 28.7, 28.7, 28.3, 28.0, 
26.2, 23.0, 21.2, 21.0, 20.8. HRMS (ESI): Calculated for C35H57N7O14S: 831.3684; Found: 
832.3695 (M+H). 
8-((tert-butoxycarbonyl)amino)octanoic acid 
 
 To a stirring solution of compound 13 (1046 mg, 7.2 mmol) in NaOH solution (34.0 mL, 
1M) and dioxane (34.0 mL).  Reaction flask was placed in an ice bath and allowed to stir at 0oC 
for 10 minutes then di-tert-butyl carbonate (2354 mg, 10.8 mmol) was added in dropwise.  
Reaction mixture was allowed to warm up to room temperature and continued to stir overnight.  
Reaction mixture was placed on vacuo to remove all dioxane, and neutralized using HCl solution 
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(1M) to pH 7.  Compound was extracted with ethyl acetate (3x), dried over sodium sulfate and 
concentrate on vacuo to yield a white solid (95% yield).  No purification was required.  NMR 
matched as reported compound.  
 
 
tert-butyl(7-((3,5-bis(prop-2-yn-1-ylcarbamoyl)phenyl)amino)-7-
oxoheptyl)carbamate  
 
 To a stirring solution of the known spacer (64 mg, 0.26 mmol) in THF (5.0 ml), CDMT 
(91 S-6 mg, 0.52 mmol) and NMM (52 mg, 0.52 mmol) was added at 0 °C for 12 hr. In a separate 
flask, the known dimeric scaffold2 was dissolved in THF (5 ml) with NMM (52 mg, 0.52 mmol) 
at 0 °C and added to the activated acid and stirred for 12 hr. The reaction mixture was quenched 
with H2O, extracted with EtOAc (10 ml, 3x), dried over Na2SO4 and concentrated in vacuo. The 
compound was purified using flask chromatography with hexane: acetone (3:1) to yield a white 
solid (96 mg, 80% yield). 1H NMR (400 MHz, CDCl3) δ 9.39 (s, 1H), 8.27 (s, 2H), 8.04 (s, 1H), 
7.75 (s, 2H), 4.80 (s, 1H), 4.17 (s, 4H), 3.00 (d, J = 6.1 Hz, 2H), 2.25 (m, 5H), 1.42 (s,15H). 13C 
NMR (100 MHz, CDCl3) δ 173.0, 166.7, 159.4, 139.4, 134.6, 121.8, 79.4, 77.4, 77.0, 76.7, 71.7, 
56.0, 37.0, 31.6, 30.9, 29.8, 28.6, 28.4, 26.3, 25.2, 22.6, 14.1. HRMS (ESI) Calculated for 
C26H34N4O5: 482.2529; Found: 505.2404 (M+Na). 
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Compound 5a:  
 
To a stirring solution of 3a (40 mg, 0.06 mmol) in THF/ water (1 ml, 1:1), 4 (9.6 mg, 0.02 
mmol) was added.  CuSO4 (10 mg, 0.04 mmol) was added along with sodium L-ascorbate (7.9 
mg, 0.04 mmol) and the reaction was stirred at rt for 12 hr. Solvent was removed in vacuo and 
product was purified using flash column chromatography with DCM:MeOH (10:1) to yield 5a 
(33 mg, 60% yield).  1H-NMR (400 MHz, CDCl3) δ  1H-NMR (400 MHz, CDCl3) δ  9.21 (s, 1H), 
8.35 (s, 3H), 8.07 (s, 3H), 6.08 (s, 2H), 5.53 (d, J = 8 Hz, 2H), 5.36-5.31 (m, 5H), 4.70 (s, 5H), 
4.32-4.29 (m, 6H), 4.07 (dd, J = 4, 12 Hz, 2H), 3.99-3.92 (m, 2H), 3.78-3.75 (m, 3H), 3.71 (s, 
6H), 3.55 (d, J = 8 Hz, 2H), 3.10 (d, J = 4 Hz, 2H), 2.72-2.65 (m, 6H), 2.55-2.51 (m, 2H), 2.38 (s, 
2H), 2.19 (m, 3H), 2.13 ( s, 6H), 2.02 (s, 6H), 1.98 (s, 6H), 1.93 (s, 6H), 1.45 (s, 12H), 1.36 (s, 
27H), 1.27 (s, 12H).  13C NMR (100 MHz, CDCl3)  δ 210.8, 172.3, 171.3, 170.7, 170.1, 170.0, 168.8, 
166.6, 156.3, 156.1, 139.7, 135.0, 134.9, 123.1, 121.5, 121.44, 121.4, 121.3, 83.5, 79.7, 79.13, 79.11, 
77.9, 77.6, 77.5, 77.2, 76.6, 76.5, 74.4, 69.5, 68.4, 68.2, 68.0, 62.4, 53.8, 52.9, 51.0, 50.3, 50.2, 
50.15, 50.08, 50.00, 40.5, 40.4, 38.8, 37.2, 37.1, 35.5, 35.4, 31.9, 31.8, 29.9, 29.8, 29.78, 29.7, 
29.6, 29.5, 29.4, 29.3, 28.8, 28.7, 28.73, 28.69, 28.65, 28.62, 28.5, 28.4, 28.3, 28.2, 28.18, 28.14, 
27,3, 27.2, 26.4, 25.9, 25.6, 25.5, 25.4, 25.3, 25.2, 23.3, 23.2, 22.7, 22.6, 21.1, 21.0, 20.8, 20.7, 
14.1.  HRMS (ESI) Calculated for C84H128N14O29S2; 1860.8413, found; 1923.6098 (M+ 3Na). 
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Compound 5b: 
 
To a stirring solution of compound 3b (26 mg, 0.04 mmol) in THF and water mixture (1 ml, 
1:1), 4 (8.6 mg, 0.017 mmol) was added.  CuSO4 (7.5 mg, 0.38 mmol) was added with sodium L-
ascorbate (6.7 mg, 0.28) and the reaction was stirred for 12hr at rt. Solvent was removed in 
vacuo and the product was purified using flash column chromatography with DCM:MeOH (10:1) 
to yield compound 5b (84 mg, 65% yield).  1H NMR (400 MHz, CDCl3) δ 11.30 (s, 2H), 8.50 (d, 
J = 27.2 Hz, 3H), 8.38 – 8.19 (m, 2H), 7.86 – 7.59 (m, 6H), 6.25 (s, 2H), 5.33 (m, 5H), 4.72 (m, 
6H), 4.34 (m, 7H), 4.21 – 4.01 (m, 9H), 3.88 – 3.69 (m, 10H), 3.11 (d, J = 6.1 Hz, 1H), 2.87 – 
2.61 (m, 5H), 2.58 – 2.44 (m, 2H), 2.38-1.87 (m, J = 7.3 Hz, 22H),  1.57 – 1.14 (m, 67H), .  13C 
NMR (101 MHz, CDCl3) δ 170.9, 170.7, 170.2, 168.7, 166.3, 162.9, 156.8, 152.5, 144.6, 134.9, 
122.9, 121.3, 114.1, 83.5, 77.3, 77.2, 77.0, 76.7, 75.0, 68.8, 67.8, 62.5, 56.1, 53.8, 52.9, 50.2, 35.5, 
31.9, 29.8, 29.7, 29.4, 29.3, 28.6, 28.4, 28.2, 27.9, 27.5, 25.8, 23.0, 22.7, 21.2, 20.9, 20.8, 14.1.  
HRMS (ESI) Calculated for:  C96H148N18O33S2; 2144.9898, found; 2145.9985 (M + H). 
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Compound SC1.   
 
 
 
To a stirring solution of compound 3a (10 mg, 16 µmol) in MeOH (1.0 mL) sodium 
methoxide (5.4 M, 250 µL) was added.  The reaction was allowed to stir for 1 hr, neutralized with 
+H resin.  The resin was filtered out, solvent was removed via vacuo and residue was re-
dissolved DCM:TFA (1:1) solution and allowed to stir for 1 hr, then solvent was removed via 
vacuo.  The residue was then re-dissolved in EtOH with Pd(OH)2 and allowed to stir for 8 hr.  
Pd(OH)2 was filtered and solvent was removed via vacuo, re-dissolved in MeOH (1.0 mL) and 
sodium hydroxide solution (10  mM, 1.0 mL) was added and allowed to stirred for 1 hour.   Acid 
resin was used to neutralize to pH 7 and solvent was removed and compounds were purified 
with Bio-Gel P-2 Gel with filtered water as solvent (yield 75%).  1H NMR (400 MHz, D2O) δ 3.72 
(t, J = 11.4 Hz, 1H), 3.60 – 3.42 (m, 2H), 3.22 (s, 1H), 2.87 (t, J = 7.6 Hz, 1H), 2.74 – 2.45 (m, 
2H), 1.92 (s, 1H), 1.52 (dd, J = 16.9, 8.7 Hz, 2H), 1.28 (s, 2H).  13C NMR (101 MHz, D2O) δ 
181.47, 174.45, 86.58, 75.30, 72.14, 68.18, 62.58, 51.81, 50.00, 40.85, 39.39, 29.43, 29.08, 27.40, 
26.49, 24.91, 23.27, 21.99.  HRMS (ESI) Calculated for:  C17H33N3O7S 423.2039, found: 
422.1962 (M-1).   
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Compound SC2. 
 
 
 
To a stirring solution of compound 3a (5 mg, 16 µmol) in MeOH (1.0 mL) sodium methoxide 
(5.4 M, 250 µL) was added.  The reaction was allowed to stir for 1 hr, neutralized with +H resin.  
The resin was filtered out, solvent was removed via vacuo and residue was re-dissolved in 
ethanol with Pd(OH)2 and allowed to stir for 8 hr.  Pd(OH)2 was filtered and solvent was 
removed via vacuo, re-dissolved in MeOH (1.0 mL) and sodium hydroxide solution (10  mM, 1.0 
mL) was added and allowed to stirred for 1 hour.   Acid resin was used to neutralize to pH 7 and 
solvent was removed and compounds were purified with Bio-Gel P-2 Gel with filtered water as 
solvent.  1H NMR (400 MHz, D2O) δ 4.25-4.08 (m, 3H), 3.99 (m, 3H), 3.58-3.55 (m , 1H),  3.36-
3.34 (m, 1H),  3.12-3.07 (m, J = 8.2 Hz, 2H),  2.95-2.78 (m, 1H), 2.44-2.35 (m, 3H), 2.15 (s, 1H), 
2.03 (s, 1H), 1.87 (s, 5H), 1.69-1.54 (m, 3H).  HRMS (ESI) Calculated for:  C18H35N5O7S 
465.2257, found:  464.1987 (M-1, negative ion). 
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Compound SC3.   
 
 To a stirring solution of compound 5a (4 mg, 2.6µmol) in MeOH (1.0 mL) sodium 
methoxide (5.4 M, 250 µL) was added.  The reaction was allowed to stir for 1 hr, neutralized with 
+H resin.  The resin was filtered out, solvent was removed via vacuo and residue was re-
dissolved in DCM and TFA (1.0 mL, 1:1 ratio) and allowed to stir for 1 hr.  Solvent was removed 
via vacuo, re-dissolved in MeOH (1.0 mL) and sodium hydroxide solution (10 mM, 1.0 mL) was 
added and allowed to stir for 1 hr.   Acid resin was used to neutralize to pH 7 and solvent was 
removed and compounds were purified with Bio-Gel P-2 Gel with filtered water as solvent (yield 
80%).  1H-NMR (400 MHz, D2O) δ 7.83-7.75 (m, 5H), 4.21 (t, J = 4 Hz, 2H), 4.01-3.95 (m, 1H), 
3.71-3.51 (m, 11H), 3.24-3.17 (m, 2H), 2.86 (t, J = 8 Hz, 2H), 2.75 (dd, J = 4, 12 Hz, 2H), 2.60-
2.52 (m, 3H), 2.42-2.39 (m, 2H), 2.26 (t, J = 8 Hz, 2H), 1.92 (s, 6H), 1.8-1.74 (m, 2H), 1.65 (t, J 
= 8 Hz, 3H), 1.55-1.49 (m, 3H), 1.36-1.02 (m, 15H).  13C-NMR (100 MHz, D2O) 175.5, 175.0, 
173.2, 168.5, 144.4, 138.2, 134.6, 123.9, 123.8, 123.9, 122.6, 122.5, 121.8, 100.0, 85.9, 74.7, 72.0, 
67.7, 62.4, 62.3, 50.8, 50.3, 47.9, 39.4, 36.4, 35.0, 29.2, 26.6, 25.1, 22.1, 13.2.  HRMS (ESI) 
Calculated for C55H88N14O17S2 is 1280.5893, found 641.3013 (M÷2). 
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Compound SC4 
 
 To a stirring solution of compound 5b in MeOH (1.0 mL) sodium methoxide (5.4 M, 250 
µL) was added.  The reaction was allowed to stir for 1 hr, neutralized with +H resin.  The resin 
was filtered out, solvent was removed via vacuo and residue was re-dissolved in DCM and TFA 
(1.0 mL, 1:1 ratio) and allowed to stir for 1 hr.  Solvent was removed via vacuo, re-dissolved in 
MeOH (1.0 mL) and sodium hydroxide solution (50 mM, 1.0 mL) was added and allowed to stir 
for 1 hr.   Acid resin was used to neutralize to pH 7 and solvent was removed and compounds 
were purified with Bio-Gel P-2 Gel with filtered water as solvent, yield white solid (70% yield).  
1H-NMR (400 MHz, D2O) δ 7.88-7.79 (m, 5H), 4.69 (s, 1H), 4.28 (d, J = 8 Hz, 1H), 4.05 ( s, 1H), 
3.87-3.79 (m, 3H), 3.71-3.60 (m, 11H), 3.52-3.42 (m, 11H), 2.86-2.84 (m, 10H), 2.70 (s, 2H), 
2.61-2.55 (m, 6H), 2.40-2.31 (m, 4H), 1.87 (s, 7H), 1.75-1.56 (m, 11H), 1.29 (m, 9H), 1.14-1.09 
(m, 10H).  HRMS (ESI) Calculated for C57H92N18O17S2 is 1364.6329, founded 1365.6420 (M+H).  
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Scheme 2. Reagents and conditions. k. DCM, TFA, 1 hr. quant. l. 1,3-Bis(tert-butoxycarbonyl) -
2- methyl -2-thiopseudourea. HgCl2, Et3N, DCM, overnight, 84%. j. Na-Lascorbate, copper 
sulfate. THF/H2O, overnight, 78%. g. NaOH, MeOH. h. DCM/TFA.70%. i. H2, Lindlar Catalyst, 
EtOH, 4 hrs. quant. 
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Compound 12: 5-Acetylamino-4- N-tert-butyloxycarbonyl-6- (1,2,3-triacetoxy-propyl) -5,6-
dihydro-4H-pyran-2-carboxylic acid methyl ester. 
 
 
 
To a solution of compound 4 101(1.50 g, 3.3mmol) in EtOH (25 mL), Lindlar catalyst (.15 g, .1 
equivalent) was added. Hydrogen gas was bubbled to the solution and stirred at rt for 12 hr. 
After filtering using celite, the filtrate was collected and solvent removed in vacuo to give a white 
product (1.42 g, quant.). To this compound (530 mg, 1.23 mmol) in THF (20 mL), Et3N (150 mg, 
1.48 mmol) was added. The solution was stirred rt for 30 min and Boc2O (538 mg, 2.46 mmol) 
was added and reaction stirred for 12 hr at rt. Upon completion, THF was removed in vacuo. The 
residue was washed using HCl (1M, 25 ml) and extracted by DCM (30 ml, 3x), the organic 
phases were combined and dried over Na2SO4. DCM was removed in vacuo and the reaction 
mixture was purified using column chromatography with hexane: acetone (3:1) as eluent to give 
a white product. (561mg, 86%). 1H NMR (400 MHz, CDCl3) δ 6.46 (d, J = 9.0 Hz, 1H), 5.94 (s, 
1H), 5.43 (s, 1H), 5.27 (s, 1H), 4.63 (d, J = 12.4 Hz, 1H), 4.44 (d, J = 10.0 Hz, 1H), 4.35 (d, J = 
8.9 Hz, 1H), 4.15 (dd, J = 12.3, 7.1 Hz, 1H), 3.95 (d, J = 9.2 Hz, 1H), 3.77 (s, 3H), 2.14 (s, 9H), 
2.10 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.95 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 170.9, 170.6, 
170.3, 170.0, 161.8, 156.2, 144.6, 111.0, 80.2, 71.4, 67.8, 62.2, 60.4, 52.4, 50.1, 47.3, 28.2, 23.1, 
21.0, 20.9, 20.8, 20.7, 14.2. HRMS. Calculated for C23H34N2O12, 530.2112. Found: 531.2181 
(M+H) 
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Compound 13: 5-Acetylamino-4- N-tert-butyloxycarbonyl-6-[(2,2- 
dimethyl-[1,3]dioxolan-4-yl] 5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester.  
 
 
To a solution of compound 7 (560 mg, 1.06 mmol) in MeOH (10 mL), MeONa (0.05 eq) was 
added. The solution was stirred at rt for 5 hr. The progress of the reaction was monitored by 
TLC. Upon completion, the reaction mixture was neutralized by H+ resin, the suspension was 
filtered. The liquid phase was collected and dried in vacuo to give a colorless compound. To a 
solution of this compound (425 mg, 1.05 mmol) in dry acetone (10 mL), H+ resin was added to 
adjust the pH to 4. The solution was stirred at rt for 12 hr. The suspension was filtered, acetone 
was removed in vacuo, the residue was washed by saturated NaHCO3, extracted by DCM (3 × 20 
mL), the organic phases were combined and dried over Na2SO4, DCM was removed in vacuum 
and the reaction mixture was purified by flash column chromatography using hexane : acetone 
(4:1) to give the product 3. (410 mg, 88%). 1H NMR (400 MHz, CDCl3) δ 6.65 (d, J = 6.4 Hz, 
1H), 5.79 (s, 1H), 5.08 (d, J = 4.2 Hz, 1H), 4.82 (d, J = 9.0 Hz, 1H), 4.59 (t, J = 9.4 Hz, 1H), 4.38 
(dd, J = 13.5, 5.3 Hz, 1H), 4.26 – 4.06 (m, 2H), 4.01 (d, J = 10.6 Hz, 1H), 3.91 (td, J = 10.1, 6.7 
Hz, 1H), 3.76 (s, 3H), 3.50 (dd, J = 8.3, 4.3 Hz, 1H), 2.03 (s, 3H), 1.44 (s, 9H), 1.40 (s, 3H), 1.36 
(s, 3H). 13C NMR (400 MHz, CDCl3) δ 173.9, 162.0, 157.2, 146.3, 109.2, 107.8, 81.0, 78.3, 77.3, 
77.0, 76.7, 74.0, 69.7, 67.3, 52.4, 52.1, 48.7, 28.2, 27.1, 25.3, 23.0. HRMS (ESI) Calculated for 
C20H32N2O9, 444.2108. Found: 445.2180 (M+H). 
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Compound 9: 5-Acetylamino-4-N-tert-butyloxycarbonyl-6- [(2,2-dimethyl-[1,3]dioxolan-4-
yl)- (4-nitro-phenoxycarbonyloxy)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl 
ester. 
 
 
 
To a solution of compound 3 (35mg, 0.079 mmol) in pyridine (10 ml), DMAP (19mg, 0.16 
mmol) was added. The solution was stirred at rt for 30 min and 4-nitrrophenylchloroformate 
(31.7mg, 0.157mmol) was added. The reaction was stirred at rt for 16 hr. The reaction mixture 
was washed by HCl (1 M, 25 ml) and extracted with DCM (3 × 20 mL), the organic phases were 
combined and dried over Na2SO4. DCM was removed in vacuo and the product was purified by 
column chromatography using hexane: acetone (3:1) to give 4. (39mg, 80%).  1H NMR (400 
MHz, CDCl3) δ 8.27 (d, J = 8.9 Hz, 2H), 7.50 (d, J = 8.9 Hz, 2H), 5.97 (d, J = 9.6 Hz, 1H), 5.90 
(s, 1H), 5.31 (t, J = 5.7 Hz, 1H), 4.81 (d, J = 9.6 Hz, 1H), 4.54 (t, J = 9.7 Hz, 1H), 4.47 – 4.29 (m, 
2H), 4.24 (dd, J = 8.9, 5.7 Hz, 2H), 4.17 – 4.05 (m, 1H), 3.79 (s, 3H), 1.95 (s, 3H), 1.42 (s, 9H), 
1.41 (s, 3H), 1.38 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 171.3, 161.6, 156.4, 155.7, 152.5, 145.6, 
144.8, 125.2, 122.3, 110.5, 108.9, 80.6, 77.3, 77.0, 76.7, 75.1, 74.2, 65.5, 52.5, 49.5, 48.1, 28.2, 
26.4, 25.5, 23.2. HRMS (ESI) Calculated for C27H35N3O13, 609.2170. Found: 632.2057 (M+Na). 
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Compound 15a: 5-Acetylamino-4-N-tert-butyloxycarbonyl-6-[(6-azido-hexyl carbamoyloxy)-
(2,2-dimethyl-[1,3]dioxolan-4-yl)-methyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl 
ester. 
 
O
N
H
N3
O
NHBoc
COOMe
AcHN
O
O O
 
 
To a solution of 6-azidohex-1-amine (19 mg, 0.13 mmol) in CH3CN (8 mL), Et3N (20mg, 0.19 
mmol) was added. The solution was stirred at rt for 30 min. 9 (39 mg, 0.064 mmol) in CH3CN 
(2 mL) was added. The reaction was stirred at rt for 3 hr. The progress of the reaction was 
monitored by TLC. Upon completion, CH3CN was removed in vacuo and the reaction mixture 
was washed by HCl (1 M, 25 ml), extracted by DCM (3 × 20 mL), the organic phases were 
combined and dried over Na2SO4. DCM was removed in vacuo and the product was purified by 
column chromatography using hexane : EtOAc (1:1) to give 5. (35 mg, 89%). 1H NMR (400 MHz, 
CDCl3) δ 6.15 (d, J = 9.4 Hz, 1H), 5.90 (s, 1H), 5.24 (d, J = 3.7 Hz, 1H), 5.01 – 4.83 (m, 2H), 4.51 
(t, J = 8.9 Hz, 1H), 4.33 (dd, J = 13.6, 7.8 Hz, 2H), 4.19 – 4.04 (m, 2H), 4.04 – 3.92 (m, 2H), 
3.76 (s, 3H), 3.73(s, 1H) 3.24 (t, J = 6.9 Hz, 2H), 3.11 (dt, J = 20.7, 6.6 Hz, 2H), 1.93 (s, 3H),  
1.66 – 1.53 (m, 2H), 1.48 (m, 2H), 1.41 (m, 2H), 1.39 (s, 9H), 1.34(s, 3H), 1.23(s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 170.8, 162.1, 156.2, 155.5, 144.4, 111.4, 108.9, 80.1, 74.9, 69.7, 65.9, 52.4, 
51.3, 50.0, 47.6, 41.1, 29.6, 28.7, 28.3, 26.4, 26.3, 26.3, 25.4, 23.2. HRMS (ESI) Calculated for 
C27H44N6O10, 612.3119. Found: 635.3006 (M+Na). 
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Compound 15b: 5-Acetylamino-4-[2,3-bis(tert-butoxycarbonyl)guanidine]-6-[(6-azido-hexyl 
carbamoyloxy)-2,3 dihydroxy propyl]-5,6-dihydro-4H-pyran-2-carboxylic acid methyl ester. 
O
N
H
N3
O
NH
COOMe
AcHN
HO
HO O
NHBoc
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To a solution of compound 10a (40mg, 0.084 mmol) in THF (3 ml),TFA (3 ml) was added, 
the reaction was stirred at rt for 1 hr. THF was removed in vacuo,  Et3N ( 26 µl, 0.25 mmol) was 
added. The solution was stirred at rt for 30 mins. HgCl2 (27 mg, 0.1mmol) and 1,3-Bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (29 mg, 1.2mmol) was added. The reaction was 
stirred at rt for 12 hr. The reaction mixture was washed with HCl (1M, 25 ml) , extracted with 
DCM (3 x 10 ml), DCM was removed in vacuo and the product  was purified by column 
chromatography using DCM : MeOH (25 :1) to give the product 10b. (50 mg, 84%). 1H NMR 
(400 MHz, CDCl3) δ 11.40 (s, 1H), 8.54 (d, J = 8.7 Hz, 1H), 7.39 (s, 1H), 7.28 (s, 1H), 6.85 (s, 
1H), 5.89 (s, 1H), 5.32 (s, 1H), 5.20 (t, J = 9.5 Hz, 1H), 5.03 (t, J = 5.7 Hz, 1H), 4.82 (d, J = 9.4 
Hz, 1H), 4.49 (d, J = 10.5 Hz, 1H), 4.37 (dd, J = 19.7, 10.0 Hz, 1H), 4.14 (dd, J = 14.2, 7.1 Hz, 1H), 
4.05 (d, J = 9.2 Hz, 1H), 3.80 (s, 3H), 3.68 (dd, J = 24.9, 12.7 Hz, 1H), 3.27 (t, J = 6.8 Hz, 2H), 
3.17 (ddd, J = 19.4, 13.4, 6.8 Hz, 2H), 1.95 (d, J = 10.0 Hz, 3H), 1.60 (dd, J = 13.8, 6.8 Hz, 2H), 
1.50 (s, 18H), 1.38 (s, 4H), 1.27 (dd, J = 7.7, 6.5 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 171.0, 
162.8, 162.4, 162.2, 162.1, 157.1, 157.1, 152.5, 144.9, 118.2, 115.3, 110.5, 83.7, 79.7, 69.4, 68.7, 
62.4, 53.5, 52.31, 51.26, 49.4, 47.1, 45.7, 41.2, 29.4, 28.7, 28.3, 28.2, 28.1, 27.9, 27.9, 26.3, 26.2, 
22.7, 8.4. HRMS (ESI) Calculated for C30H50N8O12, 714.3548. Found: 715.3627 (M+H). 
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Compound 11a:  
 
 
To a solution of 16a (54 mg, 0.088 mmol) in THF/H2O (1 ml, 1:1), 4 (18mg, 0.036mmol) 
was added. CuSO4 (15 mg, 0.1 mmol) was added along with sodium L-ascorbate (20mg, 0.1 
mmol ). The reaction was stirred at rt for 12 h. Upon completion by TLC, solvent was removed in 
vacuo and the product was purified by column chromatography using EtOAc: MeOH (30:1) to 
give 11a. (48 mg, 78%). 1H NMR (400 MHz, CDCl3) δ 8.23(s, 3H), 7.83 (s, 2H), 6.67 (s, 2H), 
5.95 (s, 2H), 5.64 (s, 1H), 5.24(s,3H), 4.60(m, 6H), 4.33(s, 8H), 4.12 (s, 8H), 3.98 (s, 2H), 3.71 
(s, 6H), 3.04 (d, J=33.2Hz, 4H)2.40 (s, 1H), 2.19 (s, 2H), 2.09 (s, 2H), 2.06 (s, 2H), 1.90 (s, 
10H), 1.68 (s, 2H), 1.44 (s, 14H), 1.26– 1.36 (m, 42H). HRMS (ESI) Calculated for C80H122N16O25, 
1706.8767. Found: 1707.8838(M+H). 
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Compound 11b:  
 
 
To a solution of 16b (40 mg, 0.056 mmol) in THF/H2O (1 ml, 1:1), 4 (13 mg, 0.025 mmol) 
was added. CuSO4 (14 mg, 0.088 mmol) was added with sodium L-ascorbate (17mg, 
0.088mmol). The reaction was stirred at rt for 12 h. Upon completion, solvent was removed in 
vacuo and the product was purified by column chromatography using EtOAc : MeOH (20:1) to 
give 9. (38 mg, 80%). 1H NMR (400 1H NMR (400 MHz, CDCl3) δ 11.38 (s, 1H), 9.74 (s, 1H), 
8.19 (m, 5H), 7.28 (s, 2H), 5.89 (s, 2H), 5.31 (s, 6H), 5.21 – 5.05 (m, 2H), 4.78 (s, 2H), 4.52 (s, 
5H), 4.17 – 3.90 (m, 4H),4.09-3.85 (m, 4H), 3.80-3.74 (m, 8H), 3.54 (s, 2H), 3.36 (s, 1H), 3.30 
– 2.72 (m, 6H), 2.35 (d, J = 13.9 Hz, 2H), 2.05 (s, 2H), 1.81 (s, 7H), 1.54 (m, 22H), 1.45 – 1.33 
(m, 12H), 1.33 – 0.99 (m, 28H), 0.90-0.84 (m, 10H). HRMS (ESI) Calculated for C86H134N20O29, 
1910.9626. Found: 1912.0572(M+H) 
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Compound SC5: 
 
 
To a solution of compound 10a (1.8 mg, .29 µmol) in MeOH (5 mL), NaOH (0.5 M, 1 ml) 
was added. The solution was stirred at rt for 2 h. The progress of the reaction was monitored by 
TLC. Upon completion, the reaction mixture was neutralized by H+ resin, the suspension was 
filtered. The filterate was collected and dried in vacuo. The residue was added to DCM/TFA (5 
ml, 1:1), the mixture was stirred at rt for 1 h. DCM was removed in vacuo, the product was 
dissolved in EtOH (5 mL), Lindlar catalyst (10%) was added. The hydrogen was bubbled to the 
solution and stirred at rt for 12 h. The suspension was filtered and the filtrate, which contained 
product SC5, was collected and crude product was purified by P2 column to give pure SC5 (1.0 
mg, 76%).  1H NMR (400 MHz, D2O) δ 5.73 (s, 1H), 4.34 – 4.23 (m, 2H), 4.16 – 4.04 (m, 2H), 
3.71 – 3.57 (m, 1H), 3.39 (dt, J = 13.3, 6.8 Hz, 2H), 3.02 (s, 4H), 1.98 (s, 3H), 1.55 – 1.30 (m, 
4H), 1.23-1.18 (m, 4H). HRMS(ESI) Calculated for C18H32N4O8, 432.2220. Found:433.2292 
(M+H). 
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Compound SC6: 
 
SC6 was synthesized in a manner similar to that of SC5 using 10b (1.6 mg, .22 µmol) 
and the crude product was purified by P2 column to give the SC6 (.75 mg, 72%).  1H NMR (400 
MHz, D2O) δ 5.63 (s, 1H), 4.38 – 4.18 (m, 2H), 4.10-3.87 (m, 2H), 3.74-3.61(m, 2H), 3.38 (t, J = 
7.2 Hz, 1H), 3.02 (s, 4H), 1.93 (s, 3H), 1.52 – 0.99 (m, 8H). HRMS (ESI) Calculated for 
C19H34N6O8, 474.2438. Found:  475.2516 (M+H). 
 
Compound SC7: 
 
To a solution of compound 11a (4.5 mg, .26 µmol) in MeOH (5 ml), NaOH (0.5M, 1 ml) 
was added. The solution was stirred at rt for 2 hr. The progress of the reaction was monitored by 
TLC. Upon completion, the reaction mixture was neutralized by H+ resin and the suspension 
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was filtered. The filtrate was dried in vacuo and DCM/TFA (1:1, 5mL) was added to the residue 
and was stirred at rt for 1 hr. After removal of solvent, the crude product was purified by P2 
column to give SC7. (2.4mg, 70%). 1H NMR (400 MHz, D2O) δ 7.89 (s, 2H), 7.80 (s, 3H), 5.91 
(s, 2H), 4.84 (d, J = 9.4 Hz, 2H), 4.54 (s, 2H), 4.47 (d, J = 10.5 Hz, 2H), 4.29 (s, 3H), 4.25 – 
4.08 (m, 3H), 3.96 (s, 4H), 3.53 (d, J = 9.8 Hz, 2H), 3.37 (dd, J = 11.9, 6.4 Hz, 2H), 2.88 (d, J = 
7.4 Hz, 4H), 1.90 (s, 6H), 1.76 (s, 2H), 1.57 (s, 2H), 1.30 (s, 6H), 1.13-1.05 (m, 14H), 0.70-0.63 
(m, 6H). HRMS (ESI) Calculated for C57H86N16O19, 1298.6255. Found: 1299.6329(M+H). 
Compound SC8:  
 
SC8 was synthesized in a manner similar to SC7 using 11b (3.5 mg, .18 µmol) and the crude 
product was purified by P2 column to give SC8. (2.0 mg, 79%). 1H NMR (400 MHz, D2O) δ 7.89 
(s, 5H), 5.80 (d, J = 17.5 Hz, 2H), 4.44 (d, J = 10.1 Hz, 2H), 4.38 (d, J = 8.5 Hz, 2H), 4.34 – 4.20 
(m, 4H), 4.16 (dd, J = 26.4, 10.1 Hz, 2H), 4.01 (dt, J = 13.9, 6.9 Hz, 4H), 3.62 (d, J = 8.8 Hz, 
2H), 3.51 (d, J = 11.6 Hz, 1H), 2.99 – 2.79 (m, 5H), 2.29 (d, J = 7.5 Hz, 2H), 1.96 (s, 2H), 1.95 – 
1.85 (m, 5H), 1.82 (d, J = 14.9 Hz, 2H), 1.71 (s, 3H), 1.54 (s, 4H), 1.27 (s, 8H), 1.20 – 1.11 (m, 
6H), 1.06 (s, 6H). HRMS (ESI) Calculated for C57H86N16O19, 1382.6691. Found: 
1383.6761(M+H). 
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 To an overnight stirring solution of compound 2.1 (1.0 g, 2.7 mmol) in THF at 0oC with 
CDMT (0.95 g, 5.4 mmol) and NMM (0.59 g, 5.4 mmol), compound 2 (1.4 g, 1.5 mmol) in THF 
was added dropwise.  Reaction mixture was allowed to stir overnight while warming to room 
temperature.  Water was added to quench reaction, reaction mixture was placed on rota vap to 
remove majority of the THF and extracted with DCM (3x).  Organic layers were combined and 
washed with brine (1x), 1M HCl (1x) then dried over NaSO4, concentrated on vacuo and purified 
using flash chromatography with DCM and MeOH as solvent (10:1), yield yellow/white solid 
(80%).  1H NMR (400 MHz, MeOD) δ 8.88 (s, 1H), 8.17 (s, 2H), 7.97 (s, 1H), 7.75 (d, J = 7.7 Hz, 
2H), 7.61 (d, J = 7.6 Hz, 3H), 7.32 (dt, J = 31.7, 7.6 Hz, 5H), 4.32 (d, J = 6.8 Hz, 1H), 4.16 (d, J = 
2.2 Hz, 5H), 3.97 (s, 1H), 3.09 (t, J = 7.0 Hz, 2H), 2.63 (s, 2H), 2.39 (t, J = 7.7 Hz, 3H), 1.77 – 
1.61 (m, 3H), 1.55 – 1.44 (m, 2H), 1.43 – 1.25 (m, 7H).  1H NMR (400 MHz, MeOD) δ 8.9, 8.2, 
8.0, 7.8, 7.7, 7.6, 7.5, 7.4, 7.3, 7.29, 7.28, 7.26, 4.3, 4.3, 4.2, 4.1,4.0 , 3.3, 3.2, 3.1, 3.0, 2.6, 2.5, 
2.4, 2.3, 2.2, 2.1, 1.7, 1.6, 1.6, 1.5, 1.4, 1.47, 1.36, 1.30, 1.2. 
 
 To a stirring solution of compound 2.2(107 mg, 0.3 mmol) was dissolved in 
DMF:Piperidine (1:1 mixture) and allowed to stir for approximately 1 hr and thin layer 
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chromatography was used to the monitor reaction. After the reaction is completed, solvent was 
removed via rota evaporator and directly went to next step.  Oil residue was dissolved in dried 
DMF and TEA (0.3mmol) was added and allowed to stir for ten minutes.  2,5-dioxopyrrolidin-1-
yl 5-((3aS,4S,6aR)-hexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanoate (NHS-activated 
Biotin, 60.6 mg, 0.6 mmol) was added and reaction was allowed to stirred for 8 hr.  The 
compound was purified with flash column chromatography with solvent system of DCM:MeOH 
(10:1) to give a white solid (62% yield).  1H NMR (400 MHz, DMSO) δ 10.20 (s, 1H), 8.98 (s, 
2H), 8.20 (s, 2H), 7.94 (s, 1H), 7.75 (s, 1H), 6.40 (d, J = 28.4 Hz, 2H), 4.36 – 4.25 (m, 1H), 4.10 
(d, J = 25.3 Hz, 5H), 3.36 (s, 2H), 3.20 – 2.98 (m, 6H), 2.82 (dd, J = 12.3, 4.6 Hz, 1H), 2.62 – 
2.49 (m, 1H), 2.33 (t, J = 7.0 Hz, 2H), 2.05 (t, J = 7.0 Hz, 2H), 1.61 (s, 3H), 1.48 (d, J = 20.7 Hz, 
3H), 1.43 – 1.35 (m, 2H), 1.31 (s, 6H).  1H NMR (400 MHz, DMSO) δ 10.20, 8.98, 8.20, 7.94, 
7.75, 6.44, 6.37, 4.32, 4.30, 4.29, 4.13, 4.07, 3.36, 3.18, 3.17, 3.15, 3.09, 3.03, 3.02, 2.84, 2.83, 
2.81, 2.80, 2.59, 2.56, 2.51, 2.35, 2.33, 2.32, 2.07, 2.05, 2.03, 1.61, 1.50, 1.45, 1.43, 1.41, 1.40, 
1.38, 1.31. 
 
 
 To a stirring solution of compound 8a (26 mg, 0.04 mmol) in THF and water mixture (1 
ml, 1:1), compound 2.3 (8.6 mg, 0.017 mmol) was added.  CuSO4 (7.5 mg, 0.38 mmol) was 
added with sodium L-ascorbate (6.7 mg, 0.28) and the reaction was stirred for 12 hr at rt. 
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Solvent was removed in vacuo and the product was purified using flash column chromatography 
with DCM:MeOH (10:1) to yield compound 2.4a (84 mg, 65% yield).  1H NMR (400 MHz, 
MeOD) δ 8.29 – 7.80 (m, 1H), 6.49 (d, J = 9.3 Hz, 1H), 5.34 (s, 1H), 4.46 (d, J = 33.0 Hz, 1H), 
4.31 (d, J = 12.0 Hz, 1H), 4.18 (s, 1H), 4.05 (d, J = 12.1 Hz, 1H), 3.89 – 3.72 (m, 2H), 3.50 (d, J = 
9.9 Hz, 1H), 3.19 (d, J = 5.7 Hz, 1H), 2.93 (dd, J = 12.8, 4.5 Hz, 1H), 2.71 (d, J = 11.5 Hz, 1H), 
2.55 (d, J = 6.4 Hz, 1H), 2.42 (s, 1H), 2.16 (s, 1H), 2.08 (s, 1H), 2.00 (s, 1H), 1.86 (s, 1H), 1.81 – 
1.59 (m, 2H), 1.53 – 1.30 (m, 8H).  13C NMR (101 MHz, MeOD) δ 171.1, 170.4, 170.1, 168.9, 83.3, 
78.9, 74.0, 68.1, 67.5, 61.9, 60.3, 55.6, 52.0, 47.9, 47.6, 47.4, 47.2, 47.0, 39.7, 39.0, 38.5, 36.5, 
35.5, 29.1, 28.5, 28.4, 28.2, 27.7, 27.3, 26.3, 25.6, 25.3, 21.5, 20.0, 19.5, 19.4. 
 
 
 To a stirring solution of compound 8b (26 mg, 0.04 mmol) in THF and water mixture (1 
ml, 1:1), compound 2.3 (8.6 mg, 0.017 mmol) was added.  CuSO4 (7.5 mg, 0.38 mmol) was 
added with sodium L-ascorbate (6.7 mg, 0.28) and the reaction was stirred for 12 hr at rt. 
Solvent was removed in vacuo and the product was purified using flash column chromatography 
with DCM:MeOH (10:1) to yield compound 2.4b (84 mg, 65% yield). 1H NMR (400 MHz, 
CDCl3) δ 11.31 (s, 1H), 9.39 (d, J = 47.5 Hz, 1H), 8.42 (d, J = 21.5 Hz, 2H), 8.22 (s, 1H), 8.08 (s, 
1H), 7.74 (s, 1H), 6.71 (d, J = 36.5 Hz, 1H), 6.25 (d, J = 60.8 Hz, 1H), 5.46 – 5.24 (m, 2H), 4.66 
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(dd, J = 40.9, 11.0 Hz, 3H), 4.35 (d, J = 9.5 Hz, 3H), 4.15 – 4.01 (m, 3H), 3.88 – 3.71 (m, 4H), 
3.33 (dd, J = 15.8, 9.1 Hz, 1H), 3.14 (s, 1H), 2.96 – 2.72 (m, 3H), 2.61 – 2.48 (m, 1H), 2.34 (d, J = 
7.2 Hz, 2H), 2.18 (d, J = 10.7 Hz, 5H), 2.11 (s, 3H), 2.05 (d, J = 8.3 Hz, 4H), 1.92 (dd, J = 12.9, 
6.4 Hz, 3H), 1.85 (s, 3H), 1.63 (d, J = 8.8 Hz, 2H), 1.48 (d, J = 8.9 Hz, 19H), 1.42 – 1.31 (m, 7H), 
1.27 (s, 10H).  13C NMR (101 MHz, CDCl3) δ 170.9, 170.8, 170.2, 168.7, 166.6, 156.8, 152.6, 144.8, 
134.7, 123.0, 83.4, 77.3, 77.2, 77.0, 76.7, 75.2, 68.9, 67.8, 62.4, 60.4, 53.8, 52.9, 50.2, 38.7, 31.7, 
29.9, 29.7, 29.2, 28.9, 28.6, 28.2, 28.0, 27.9, 26.0, 23.0, 21.2, 21.0, 20.8, 14.2. 
 
 
To a stirring solution of compound 2.4a in MeOH (1.0 mL) sodium methoxide (5.4 M, 250 µL) 
was added.  The reaction was allowed to stir for 1 hr, neutralized with +H resin.  Solvent was 
removed via vacuo, re-dissolved in MeOH (1.0 mL) and sodium hydroxide solution (50 mM, 1.0 
mL) was added and allowed to stir for 1 hour then neutralized with acid resin. The resin was 
filtered out, solvent was removed in vacuo and the residue was re-dissolved in DCM and TFA 
(1.0 mL, 1:1 ratio) and allowed to stir for 1 hr. Solvent was removed and compounds were 
dissolved in DI water then purified with Bio-Gel P-2 Gel with filtered water as solvent, yield 
white solid (70% yield).1H NMR (400 MHz, D2O) δ 7.98 – 7.81 (m, 5H), 4.27 (s, 2H), 4.06-4.03 
(m, 2H), 3.74-3.66 (m, 7H), 3.56 (d, J = 8.6 Hz, 4H), 3.34-3.23 (m, 4H), 3.05 (s, 3H), 2.74-2.70 
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(m, 6H), 2.64-2.58 (m, 4H), 2.53 – 2.40 (m, 2H), 2.31-2.32 (d, J = 6.8 Hz, 2H), 1.95 (s, 6H), 1.74 
(s, 4H), 1.45-1.39 (m, 14H), 1.26 – 1.03 (m, 16H). 
 
To a stirring solution of compound 2.4b in MeOH (1.0 mL) sodium methoxide (5.4 M, 250 µL) 
was added.  The reaction was allowed to stir for 1 hr, neutralized with +H resin.  Solvent was 
removed via vacuo, re-dissolved in MeOH (1.0 mL) and sodium hydroxide solution (50 mM, 1.0 
mL) was added and allowed to stir for 1 hour then neutralized with acid resin. The resin was 
filter out, solvent was removed in vacuo and residue was re-dissolved in DCM and TFA (1.0 mL, 
1:1 ratio) and allowed to stir for 1 hr.     Solvent was removed and compounds were dissolved in 
DI water then purified with Bio-Gel P-2 Gel with filtered water as solvent, yielding a white solid 
(75% yield).1H NMR (400 MHz, D2O) δ 8.02 – 7.82 (m, 5H), 4.06 – 3.65 (m, 4H), 3.51 (dd, J = 
19.5, 11.7 Hz, 3H), 3.14 (t, J = 18.8 Hz, 2H), 2.83 (d, J = 82.0 Hz, 1H), 2.63 (s, 1H), 2.55 (d, J = 
11.9 Hz, 1H), 2.34 (d, J = 18.5 Hz, 1H), 2.12 (d, J = 20.9 Hz, 1H), 1.83 (s, 3H), 1.61 (s, 2H), 1.43 
(s, 1H), 1.31 (d, J = 21.8 Hz, 4H), 1.07 (s, 1H). 
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4.1 Abstract 
We have synthesized a panel of bivalent S-sialoside analogues along with six S-sialosides 
norbornene based polymers, with modifications at the 4 position, as inhibitors of influenza 
virus. These first generation compounds show IC50 values ranging from low micromolar to high 
nanomolar in enzyme inhibition and plaque reduction assays with two intact viruses, Influenza 
H1N1 (A/California/07/2009) and H3N2 (A/Hongkong/8/68). 
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4.2 Introduction 
 N-acetyl neuraminic acid or sialic acid is a known substrate that will bind to influenza 
HA and NA. In the case of HA, only NeuAcα2, 3 Gal and NeuAcα2, 6 Gal linked are recognized 
to facilitate the endocytosis process.  The variation in binding can varies between 2,3 and 
2,6glycosidic links depending on the lineage of the HA.15  NA on the other hand, its function is to 
cleave O-linked sialic acid residues and therefore will recognize sialic acid residues regardless 
where the glycosidic bond is located.  In combatting the spread of influenza, scientists have 
developed several FDA approved transition state analogs that inhibit NA from cleaving the sialic 
acid on infected cell surface.102  Oseltamivir and Zanamivir are transition state analogs that 
essentially arrest the virus progeny from escaping the cells surface.  However, some strains of 
influenza have been shown to developed resistant to both Oseltamivir and Zanamivir.103In 
recent years, a new class of NA inhibitorshave been reported to have high inhibition properties 
against broad spectrum of influenza strains, including resistant strains.49, 67  Unlike the 
transition state analogs, these compounds resemble the natural state sialic acid, where the 3rd 
and 4th position were modified to enhance inhibition properties.   
 Labeling experiments have shown that influenza viruses normally have approximately 
200-300 copies of trimeric HA and 50-100 copies of tetrameric NA.104, 105  Thus, multiple 
strategies have been developed to target both HA and NA.  Similar inhibitors were developed 
following Nature’s method using multivalency to target HA and preventing viral entry.  The 
innate human immune system respond in a very similar fashions by producing mucin, an 
endogenous sialylate proteins released by respiratory epithelial cells.  Mucin capture viral 
particles by virtue of their multiple sialic acid residues that will bind to both HA and NA, and 
purged them via a natural process known as sneezing or coughing.106, 107, 108  Similarly, 
glycopolymers and glycodemdrimers of sialic acid have been generated to capture influenza 
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viruses.  It has been shown that the increase in valencyof sialic acid increase the inhibitory effect 
significantly.  The IC50 values of mono/di/tri saccharide can improve from micromolar to 
submicromolar range.109, 110, 111  Hence, we want to take advantage of the multivalent effects and 
introduced dimeric and polymeric sialic acid analogs to investigate the IC50 value of these 
analogs. 
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Figure 30  Structure of N-acetyl neuraminic acid analogs 
Figure 31:  Structures of N-acetyl neuraminic acid (sialic acid) analogs. (A) Sialic acid with the 
numbering scheme. (B) Oseltamivir  (C) Zanamivir , (D) Premavir  (E–F)Fluorogenic substrate 
of sialic acid for obtaining IC50 values. 
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4.3 Design and Synthesis of Bivalent S-linked sialic acid  
 In previous the chapter, we have reported our sialic acid analogs are able to capture the 
influenza viral particles with biological sensitivities.98  Based on previous studies, we want to 
further investigate these analogs for potential NA inhibition properties.  However, as inhibitors 
these molecules do not require any functionalities use for immobilization, therefore the dimeric 
scaffold is not required.  First, we want to investigate the effects of the spacer length for our 
dimeric analogs.  Second, after optimization of the appropriate spacer, we want to attach these 
analogs onto a handle that will allow us to easily polymerize these compounds to increase the 
multivalency.  The design and synthesis shown in Scheme 1 and 2.  The synthesis begin with 
known azido compound 4, hydrogen chloride was added across the double bond, following by 
SN2 type replacement of the chloride by a thioacetate to introduce the sulfur moiety at the 
anomeric center with good yield.  1H and 13C NMR spectroscopy were done to confirmed that the 
α-anomeric conformation in compound 23 before pursuing forward.  Reaction of compound 23 
with hydrophobic six carbon space was done in the present of diethylamine to yield compound 
24.  Next, azido compound 25 was reduced via trephenyl-phosphine to yield amine 3.2, which 
is subsequently protected with t-butylcarbonyl group or reacted with a suitable protected 
guanidinium group to yield 26 and 27 respectively.  Removal of esters group under basic 
conditions follows by the removal of t-butylcarbonyl group with acidic condition to afford SA 
and SG in good yield.   
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Figure 31  Synthesis ruote for monomeric S-linked sialic acid 
Figure 32:   Synthesis ruote for monomeric sialic acid. a) HCl, KCl, CH3CN, 5 days  b) KSAc, 
TBTAS, DCM:H2O(1:1) 50% after 2 steps  c) S-(6-(tert-butyldimethylsilyl)hexyl) ethanethioate, 
DMF, DEA 65%  d) PPh3, THF:H2O, 40% overnight  e) (Boc)2O, TEA, THF 65% over two steps  
f) MeS(=NBoc)NHBoc, HgCl2, DCM 80% over two steps  g) i.  KOH, THF:H2O:MeOH 2 hrs, ii.  
TFA:DCM, 1hr. 
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We have used a series of activated homobifuntional hydrophobic and hydrophilic linkers 
to produce the dimeric compounds, shown in Scheme 2.  Multiple spacers were used because 
the bivalent molecules can interact with viral NA in three ways.  The bivalent molecules can 
crosslink adjacent NAs on the same tetramer or crosslink two NAs from two different NA 
tetramers on the same viral particle or crosslink NA’s from two different viral particles.  The 
minimal required distances between NA’s in all three cases are approximately 16, 30, 50 Å, 
respectively.112  Thus, by using a series of activate hydrophilic and hydrophobic spacers, we 
generated a panel of Gemini compounds 28-32 with decent yield.  The removal of ester groups 
from azido compounds 28-32 was done in basic conditions and were reduced via palladium 
catalyzed hydrogenation to yield bivalent compound amine at the 4th position.  The deprotection 
and reductions resulted in final amine compounds with good yield (C6-SA, C12-SA, TetraEG-
SA, PentaEG-SA, HexaEG-SA).  The azido intermediate 28-32 were reduced via palladium 
catalyzed hydrogenation to introduce the amine at the 4th position and was directly protected 
guinidinium group to yield compounds 33-37 with decent yield.  The removal of the ester from 
compounds 33-37 were done in basic conditions and follow by the removal of t-butylcarbonate 
in acid condition to afford final compounds in good yield (C6-SG, C12-SG, TetraEG-SG, 
PentaEG-SG, HexaEG-SG).  All intermediates and final compounds were confirmed with 
mass spectroscopy, 1H-NMR and 13C-NMR spectroscopy.   
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Figure 32  Synthesis of bivalent analogs of S-linked Sialosides 
Figure 33: Reagents and Conditions: a) DEA, DMF; 76–85%; (b) (i) NaOH/CH3OH (aq), (ii) 
H2/Pd(OH)2; 90–92% over 2 steps; (c) i. NaOMe, MeOH  ii. NaOH (50mM) iii. DCM:TFA 
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4.4 Design and Synthesis of S-linked Sialosides Polymers 
 In earlier chapters we have shown that our compounds can act as capture 
molecules to capture the influenza virus through assay.98  Further we have also shown 
our dimeric sialoside analogs have potential therapeutics against two influenza strains 
H1N1 (A/California/07/2009) and H3N2 (A/HongKong/8/68).93  Here we report the 
synthesis of sialoside polymers and their inhibition properties.  Previous studies have 
shown that our compounds have the abilities to bind to the influenza neuraminidase.93, 
98  Thus, it was logical for us to investigate their inhibition property against more 
influenza virus strains.  We have also shown that these sialoside analogs can inhibit 
intact viral particles via plaque reduction assays, therefore we want to see if increasing 
the multivalency of these analogs would decrease the IC50.  According to our previous 
studies, the IC50 value for our dimeric sialoside compounds are in high nanomolar 
range.93  Therefore, we are hypothesizing that by increasing the sialoside units on one 
molecules increase the inhibition properties and thus decrease the IC50 values due to the 
multivalent effects.113  We have molecularly attached compound 1.9a and 1.9b to an 
exo-5-norbornenecarboxylic acid as the building blocks for our polymers. 
 The advancement of ring-opening metathesis polymerization (ROMP) has made 
it the most widely use polymerization method.114  Well defined olefin-metathesis 
catalysts such as; [(tBuO)2(ArN)Mo=CH(tBu)](38) and [(PCy3)2(Cl)2Ru=CHPh] (Cy-
cyclohexyl) (39) has aided in controlling the growth of the living polymer, which has 
also made ROMP a novel method to synthesize polymers with various functional 
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groups.115, 116  Second generation Grubb’s catalyst (40) exhibits high polymerization 
activities and also high tolerance to varieties of functional groups better than compound 
41.117, 118, 119   Therefore, we have selected second generation Grubbs' catalyst (42) as our 
catalyst to carry out ROMP. 
 
Figure 33  Grubb's second generation catalyst for ROMP (43) 
 Carbon-carbon double bond (C=C) is the starting point for many organic 
reactions.  Among which, olefin metathesis reaction allows the formation and the 
breaking of carbon-carbon double bonds.  The process is mediated by a metal carbene 
catalyst Figure 4.119  The mechanism occurs when the olefin binds to the metal carbene 
catalyst, which results in the formation of metallocyclobutane.119  The metallocyclic 
intermediate species can either form new olefin and the metal carbene or revert back to 
the original species (Figure 35a).  ROMP is a type of olefin metathesis and driven by 
the release of ring strain inherent in the monomers (Figure 35b). 
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Figure 34  Mechanism of olefin metathesis 
Figure 35:  A) Olefin metathesis mechanism.  B) ROMP mechanism with initiation, 
propagation and termination steps.120  Initiation steps involves the coordination of the 
cyclic olefin to an alkylidene metal complex.  Subsequently forms a metallocyclobutane 
intermediate via a [2+2] cycloaddition.  The metallocyclic intermediate undergoes a 
cycloreversion to yield a new metal alkylidene.  The cycle continues until equilibrium is 
reach or the reaction is quenched. 
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4.5 Procedures 
 Norbornene was selected as our monomer building blocks due to their ability to 
easily undergo ROMP and polymerization is easy to control.115, 121  Thus, our synthesis 
begin with commercially available compound 38, where the free acid group was 
activated with CDMT/NMM and reacted with 1.1 equivalent of propargyl amine to yield 
compound 39 in good yield.72  Next, compound 1.9a and 1.9b can be introduced onto 
compound 39 via copper (I) catalyzed 1,3 dipolar addition to yield compound 40 and 41 
respectively with good yield.  Zemplén deprotection to remove the acetates and methyl 
ester was followed by acidic removal of the tert-butoxy groups to yield the monovalent 
compounds SA and SG which had an amine and a guanidine group at the four position 
of the sialic acid, respectively from compound 40 and 41. 
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Figure 35  Synthesis of sialoside polymers 
Figure 36:  Reagent and conditions;  a) Propargyl amine, CDMT, NMM, THF 90%  b)  
1.9a or 1.9b sodium ascorbate, CuSO4, THF:H2O:t-BuOH (1:1:1) 57%, 70% respectively  
c) Ru-initiator (4.3, 1:25, 1:10, 1:5 molar ratio) anhydrous THF (quant.)  d) i. LiOH, 
H2O ii. TFA:DCM (SA-25, 10, 5 – 80%, 75%, 80%, SG-25, 10, 5 – 75%, 85%, 60%). 
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 Polymerization of the glycomonomer 40 and 41 with a second generation olefin 
metathesis Ru-initiator 43122, 119, 123 in anhydrous tetrahydrofuran (THF) for 6 hours 
followed by chain termination with ethyl vinyl ether afforded desired polymers (42 
a,b,c and 43a, b, c).  The molecular equivalent ratio of initiator to glycomonomers 
used were; 1:25, 1:10, 1:5.  Polymerization proceeded efficiently, the process was 
monitored by TLC.  Fully protected glycopolymers 42a, b, c and 43a, b, c were 
subjected to global deprotection of acetates and methyl esters via Zemplén methods and 
then removal of tert-butoxy groups by acidic conditions.  The global deprotections of 
acetates, methyl esters and tert-butoxy groups resulted in a pale white foamy solid after 
lypolization for all six glycopolymers (SA-25, SA-10, SA-5, SG-25, SG-10, SG-5). 
4.6 Biological Assays 
Next, we subjects these NA’s inhibitors to a number of assays.  First, we use 
commercially available 2’-(4-methyllumbelliferyl)-α-D-N-acetylneuraminc acid (MUNANA) as 
substrate with water soluble viral NA before testing with intact virus.Initial binding component 
is necessary for inhabitation, we premix the compounds with NA and following the cleavage of 
the substrate over two hours to obtain the IC50 values using the linear slope between 0-35 
minutes.  The IC50 values with three independent experiments for each compound are given in 
Table 4 and the selected raw data is presented in the Supplemental data.  We used commercial 
available drugs, Zanamivir and Oseltamivir as our controls.  The results confirmed our expected 
values for sialic acid (millimolar inhibition) and the antivirals (nanomolar inhibition).  
Introduction of an amine group at the 4th position decrease the IC50 value by at approximately 
1000 fold to the micromolar range for both influenza viral enzyme N1 and N2; the IC50 values 
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for SA range from 60-180 µM.  The bivalent compounds (C6-SA, C12-SA, TetraEG-SA, 
PentaEG-SA and HexaEG-SA) all exhibit higher inhibition activity, approximately four to five 
times increase in inhibition property, especially N1 enzyme when compared to the monovalent 
compound.  However, there were exception, the compounds with the longer spacer (PentaEG-
SA and HexaEG-SA), were not that efficacious compared to the monomeric compounds.  
Similar observation were seen with N2 enzyme, where the bivalent compounds exhibiting a 
twofold higher inhibition compared to the monomeric amine containing compound and the 
longer spacer compounds are less effective.  The effectiveness of the inhibitors were enhanced 
with the introduction of the guanidine group.  The IC50 value ranging from 0.2-2.5 µM for SG, 
C6-SG, C12-SG, TetraEG-SG, PentaEG-SG and HexaEG-SG.  The IC50 values for the 
bivalent compounds, irrespective of the spacers, are similar to SG, which is the monomeric 
compounds and the values for both enzymes are similar, in the submicromolar range.  This is 
due to the soluble NA’s not being part of the membrane and some present as a mixture of 
monomers, dimers, trimers and some are tetramers.  In summary, these experiments confirm 
that the compounds with amine at the 4th position (SA, C6-SA, C12-SA, TetraEG-SA, 
PentaEG-SA and HexaEG-SA) are better inhibitors than the nature receptor.  Compounds 
with the guanidine group at the 4th position (SG, C6-SG, C12-SG, TetraEG-SG, PentaEG-
SG and HexaEG-SA) are better inhibitors than compounds with the amine at the same 
position.  We also confirmed that both classes of NA, NA1 with the more open biding pocket and 
are more flexible loop that closes upon the introduction of sialic acid or an inhibitors and NA2, 
which has a preset binding pocket, are inhibited very well by the synthetic compounds.   
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Table 3  IC50 values from MUNANA based assays 
 Virus Strains NA from virus 
Compounds Name H3N2 (µM) H1N1 (µM) H5N1 (µM) H3N2 (µM) 
SA 64±14 56±6 127±29 1778 ± 20 
C6-SA 11.6±3.5 9.9±1.8 20±5 32 ± 5 
C12-SA 15±9 11±1 31±7 40 ± 1 
TetraEG-SA 11±5 9.8±2.4 28±3 39 ± 14 
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PentaEG-SA 21±3 36±4 64±14 178 ± 20 
HexaEG-SA 33±15 45±1 85±12 216 ± 56 
SG 0.55±0.02 0.8±0.1 0.1 ± 0.002 1 ± 0.1 
C6-SG 0.25±0.05 0.26±0.003 0.2 ± 0.002 4.2 ± 1.2 
C12-SG 0.5±0.3 0.8±0.006 0.73 ± 0.003 12 ± 2 
TetraEG-SG 1.78±1.3 2.4±0.4 2.5 ± 0.1 10 ± 1 
PentaEG-SG 1±0.06 1.2±0.2 1.1 ± 0.1 10 ± 2 
HExaEG-SG 0.5±0.6 0.9±0.1 0.57 ± 0.006 11 ± 2 
Zanamivir ≈ 0.001 ≈ 0.01 ≈ 0.04 ≈ 0.04 
Oseltamivir ≈ 0.008 ≈ 0.01 ≈ 0.05 ≈ 0.05 
 
  
 
 
 
 
Our compounds were able to inhibit water soluble NA’s, we performed the same assay 
with two intact viruses, Influenza H1N1 (A/California/07/2009) and H3N2 
(A/HongKong/8/68) to ensure that the compounds are able to inhibit the transmembrane NAs 
present on the viruses.  A similar trend was observed for soluble NA, SA the compounds with 
the amine at the 4th position, exhibit an IC50 value of 60 µM for both strains.  The bivalent 
comlecules, C6-SA, C12-SA, TetraEG-SA, PentaEG-SA and HexaEG-SA exhibit a 5-fold 
decrease in the IC50compared to the monomer to ≈ 10 µM.  The lone exception is the compound 
with the longest oligoethylene glycol spacer, which did not have a similar effect as the other 
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bivalent molcules, presumably because of the spacer is too flexible to exhibit a bidentate effect.  
In the case of the guanidine containing compounds, the mnomerSG has an IC50 of ≈ 1 µM for 
both strains, which is a 50-fold decrease when compared to SA compound.  The bivalent 
compounds, C6-SG, C12-SG, TetraEG-SG, PentaEG-SG, and HexaEG-SG all show 
significant decrease in the IC50 values, ranging from 250 nM to 2.4 µM for both viruses, with 
C6-SG the best inhibitor of all compounds.  However, since the values for all bivalent copounds 
are similar, it is not clear if the compounds bind to the NA’s on the same viron or different 
virons.  What is clear, is that our hypothesis increasing the intrinsic binding affinity of an 
individual sialoside analogs coupled with bivalency decrease the IC50 values from the millimolar 
ranging by 10,000 fold to nanomolar range. 
 
 
 
 
 
 
 
Table 4  IC50 values from plaques based assays 
 Virus Strains 
Compounds Name H3N2 (µM) H1N1 (µM) 
SA 10-100 >100 
C6-SA 1-10.0 >100 
121 
 
 
C12-SA 1-10.0 >100 
TetraEG-SA 1-10.0 >100 
PentaEG-SA 1-10.0 >100 
HexaEG-SA 1-10.0 >100 
SG 1-10.0 >10 
C6-SG 0.001-0.1 >1 
C12-SG 0.1-0.11 > 
TetraEG-SG 0.1-0.11 >1 
PentaEG-SG 0.1-0.11 >1 
HExaEG-SG 0.1-0.11 >1 
Zanamivir 0.001-0.01 ≈ 0.01 
Oseltamivir 0.001-0.01 ≈ 0.01 
 
 
 
 
 
 
 We were also interested in testing the efficacy of these compounds to inhibit the virus in 
cell base systems.  Toward that end, we performed a plaque assay for all the compounds.  The 
viruses was introduced to the cells for 30 min, followed by addition of the compounds to arrest 
the spread of the viruses.  IC50 values based on 50% plaque reduction in plaque size are given in 
Table 2.  We were please to observe a similar trend for all compounds as was seen with the cell 
free system.  The SA compound with an amine at the 4th position exhibit inhibition in the 10-
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1000 µM range for both H1N1 and H3N2 strains and the dimers C6-SA, C12-SA, TetraEG-
SA, PentaEG-SA and HexaEG-SA, exhibiting a 10-fold decrease in the IC50 values (range 
from 1-100 µM) in comparison to SA.  The bivalent derivatives C6-SG, C12-SG, TetraEG-SG, 
PentaEG-SG and HexaEG-SG, all exhibiting lower IC50 value (10-1000 nM) than SG. 
4.7 Summary 
 In summary, we have combined robustness of S-sialosides, increased intrinsic affinity of 
a single nit and used bivalency to produce a panel of compounds that inhibit two different 
strains of influenza viruses.  The IC50 values range from the low micromolar to high nanomolar.  
We have also identified the appropriate length of the spacer for attachment of an appropriate 
scaffold, longer spacers such as a pentra or hexa ethylene glycol do not seen to increase the 
effectiveness of the inhibitors.  Finally, we note that these compounds are not as efficacious as 
Zanamivir or Oseltamivir.  However, we are currently making structural modifications, for 
example introducing a fluorine at the 3 position and tethering the molecules 
polymeric/dendrimeric scaffold.  We anticipate that these modifications will enhance the IC50 
values to produce highly potent inhibitors.  
 
 
 
4.8 Experimental 
a. Synthesis of S-sialomonomers. 
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Scheme 1. Synthesis of SA and SG. Reagents and Conditions: a)  HCl (g), LiCl, CH3CN, 6 
days; b) KSAc, TBAB (Tetrabutylammonium bisulfate), CH2Cl2/H2O, overnight, 50% over 2 
steps; c) TosOC6H12SAc, DEA, DMF, 65%; d) PPh3, THF/H2O, 12h; e) (Boc)2O, TEA, THF, 60% 
over 2 steps f) MeS-(C=NBoc)NHBoc, HgCl2, TEA, CH2Cl2, 80% over 2 steps; g) MeOH/NaOH 
(aq), 1 h; h) TFA/DCM (1:1). 90% over two steps for SA and SG, respectively.   
 
 
Methyl (5-acetamido-7, 8, 9-tri-O-acetyl-4-azido-2-chloro-3, 4, 5-trideoxy -β-D- 
glycerol -D-galacto-2-nonulopyranosid)onate 2. Anhydrous HCl was bubbled through a 
solution of glycal 1 (1g, 2.1 mmol) in CH3CN (20 ml) containing LiCl (500 mg, 11.7 mmol) for 30 
min. The reaction mixture was stirring at room temperature for 4 days. HCl gas was bubbled 
again for 30 min through the solution again and the reaction was stirred for 2 more days. The 
solvent was evaporated to dryness, suspended in CH2Cl2, washed with ice-cold saturated 
NaHCO3, dried over Na2SO4, concentrated to dryness. The crude material was directly used in 
next step. 
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Methyl (5-acetamido- 7, 8, 9-tri-O-acetyl-4-azido-2-thioacetyl-3, 4, 5-trideoxy -α-D- 
glycero-D-galacto-2-nonulopyranosid) onate 3. KSAc (1.25 g, 0.01 mmol, 5eq based on 1) 
and TBAB (740mg, 2.2 mmol, 1eq based on 1) were dissolved in water; a solution of crude 
chloride in CH2Cl2 was added dropwise. The two phase reaction system was stirred for 12 h. The 
organic phase was extracted by CH2Cl2 and washed with water, dried over Na2SO4. The solvent 
was removed in vacuum to give a residue, which was purified by flash chromatography to afford 
the title compound (580 mg, 50%) and 1 as a mixture (molar ratio 1:1 determinated by NMR).  
 
6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy -D- glycero-α-
D-galacto-non-2-ulopyranosyl) onate]-1-thiolacete -hexane 4. Thioacetate 3 (200 mg, 
0.37 mmol) and TosOC6H12SAc (88.6 mg, 0.3 mmol) were dissolved in dry DMF (8 ml). DEA 
(312 µL, 3 mmol) was added dropwise and the reaction mixture was stirred for 2 h at room 
temperature. The solvent was removed in vacuo and the residue was purified by flash column 
chromatography to give the product as a colorless oil (215 mg, 65%). 1H NMR (400 MHz, CDCl3) 
δ 5.64 (d, J = 8.3 Hz, 1H, -NHAc), 5.35-5.29 (m, 2H, H-7, H-8), 4.31 (d, J = 11.4 Hz, 1H), 4.20 
(dd, J = 12.5, 4.3 Hz, 1H), 4.09 (d, J = 10.7 Hz), 3.99 (br, 1H), 3.83 (d, J = 10.5 Hz, 3H), 3.32-
3.31 (m, 1H), 2.87 (t, J = 7.3 Hz, 2H), 2.82 – 2.63 (m, 2H, -SCHa, H-3eq), 2.62 – 2.45 (m, 1H, -
SCHa), 2.33, 2.17, 2.05, 2.00 (4s, 12H), 1.86 – 1.32 (m, 8H). 13C NMR (101 MHz, CDCl3) δ 195.9, 
170.9, 170.5, 170.1, 169.8, 168.3, 162.5, 82.9, 77.5, 77.2, 76.8, 73.5, 68.5, 67.4, 62.0, 58.7, 52.7, 
50.3, 38.0, 36.5, 31.4, 30.5, 29.2, 29.0, 28.9, 28.6, 28.1, 28.0, 23.1, 21.0, 20.8, 20.6. ESI-HRMS 
calcd for C26H41N4O11S2: 649.2213, found: m/z 649.2230 [M + H]+; C26H40N4O11S2Na: 671.2038, 
found: m/z 671.2033 [M + Na]+. 
 
6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) onate] -
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1-thioacetyl-hexane 7. A solution of azide 4 (200 mg, 0.33 mmol) and PPh3 (0.4 mmol) in 
THF/H2O (1:1, 10 ml) was stirred overnight. The solvent was removed in vacuo. The crude 
product 5 was dissolved in anhydrous CH2Cl2, and TEA was added dropwise to obtain a clear 
solution. Then 1, 3-bis (tert-butoxycarbonyl)-2-methylthiopseudourea (115 mg, 0.4 mmol) and 
HgCl2 (109 mg, 0.4 mmol) was added under 0 ℃. The solution was warmed to room 
temperature and stirred for 12 h to obtain a suspension. The reaction was filtered. The filtrate 
was concentrated and purified by silica gel chromatography to obtain title compound 7 as a 
colorless amorphous solid (135mg, 80% over two steps). 1H-NMR (400 MHz, CDCl3) δ 11.29 (s, 
1H, NHBoc), 8.39 (1H, d, J=6.8 Hz, -NHBoc), 6.01 (1H, d, J=8.8 Hz, -NHAc), 5.39-5.30 (m, 2H, 
H-7, H-8), 4.34 (dd, 1H, J=2.0, 12.0 Hz, H-9a), 4.10-4.00 (m, 3H, H-9b, H-6, H-4), 3.83 (s, 3H, 
-OMe), 3.81-3.76 (m, 1H, H-5), 3.54 (t, 2H, J=6.8 Hz, -CH2SAc), 2.82-2.72 (m, 2H, -SCHa-, H3eq 
), 2.58-2.53 (m, 1H, -SCHb-), 2.17, 2.14, 2.04, 1.86 (4s, 4×3H, 4×-CH3CO), 1.89-1.21 (m, 26H); 
13C NMR (101 MHz, CDCl3) δ 195.9, 170.7, 170.6, 170.1, 170.1, 168.7, 162.9, 156.7, 152.6, 83.8, 
83.3, 79.4, 77.3, 77.0, 76.7, 75.4, 69.0, 67.7, 62.3, 52.8, 50.4, 49.7, 38.8, 30.6, 29.3, 29.2, 29.1, 
29.0, 28.7, 28.3, 28.2, 28.2, 28.0, 23.0, 21.2, 20.9, 20.7. ESI-HRMS calcd for C37H61N4O15S2: 
865.3575, found: m/z 865.3590 [M + H]+.  
 
6-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy -4-(N-tert-
butyloxycarbonyl)-amino-D-glycero-α-D-galacto-non-2-ulopyranosyl)onate] -1-
thioacetyl-hexane 6. The crude product 5 (1 mmol) was dissolved in THF, (Boc)2O (218 mg, 1 
mmol) was added and the reaction mixture was stirred at room temperature for 24 h. The 
reaction mixture was concentrated under reduced pressure. The crude product was purified by 
silica gel chromatography to obtain title product as a colorless amorphous solid (134 mg, 
60%).1H NMR (400 MHz, CDCl3) δ 5.60 – 5.21 (m, 3H), 4.70 (d, J = 8.4 Hz, 1H), 4.31 (d, J = 
12.0 Hz, 1H), 4.11 (dd, J = 12.4, 4.2 Hz, 1H), 4.03 – 3.70 (m, 5H), 3.53-3.52 (m, 1H), 2.86 (t, J = 
7.3 Hz, 1H), 2.79 – 2.70 (m, 2H), 2.55-2.48 (m,1H), 2.32, 2.16, 2.12, 2.04, 1.90 (5s, 5OAc), 1.75-
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1.69 (m, 1H), 1.56 – 1.26 (m, 17H); 13C NMR (101 MHz, CDCl3) δ 195.9, 170.9, 170.6, 169.9, 
168.6, 155.9, 83.4, 79.9, 77.3, 77.0, 76.7, 74.8, 68.5, 67.4, 62.1, 52.9, 50.2, 50.1, 39.2, 30.6, 29.3, 
29.1, 29.0, 28.7, 28.3, 28.2, 28.2, 23.2, 21.1, 20.7. ESI-HRMS calcd for C31H50N2O13S2Na: 
745.2652, found: m/z 745.2657 [M + Na]+.  
 
6-S-[5-acetamido-3, 4, 5-trideoxy-4- amino-D-glycero-α-D-galacto-enonic acid] -1- 
thiol -hexane SA. 6 was treated with MeOH and 1 M NaOH. After stirred for 1 h, the solution 
was neutralized to pH 7 with Dowex 50W X 8 (H+) resin, filtered and evaporated to dryness. 
Then TFA/DCM (1:1) was added, and the reaction mixture was stirred for 2 h at room 
temperature. The solution was evaporated to dryness. The residue was lyophilized to get a 
colorless amorphous solid (90%). 1H NMR (400 MHz, MeOD) δ 4.19-4.14 (m, 1H); 3.85-3.61 (m, 
5H), 3.44-3.32 (m, 1H); 2.90-2.67 (m, 5H, HSCH2-, -SCH2-, H3eq), 2.02 (s, 3H, -NHAc), 1.57-
1.28 (m, 8H); 13C NMR (100 MHz, MeOD) δ 174.8, 172.5, 75.5, 71.5, 68.2, 62.9, 50.6, 38.1, 36.2, 
28.9, 28.8, 28.6, 28.1, 27.5, 21.5. ESI-HRMS calcd for C17H33N2O7S2: 441.1729, found: m/z 
440.1639 [M + H]+. 
 
6-S-[5-acetamido-4-guanidino-3, 4, 5-trideoxy -D-glycero-α-D -galacto-non-2 -
ulopyranosyl) onate]-1-thiol-hexane SG. 
The guanidine compound 7 was deprotected with the same procedure described above to get a 
colorless amorphous solid (90%). 1H NMR (400 MHz, D2O) δ 3.72-3.30 (m, 7H), 2.64-2.51 (m, 
5H, HSCH2-, -SCH2-, H3eq), 1.81 (s, 3H, -NHAc), 1.57-1.28 (m, (m, 8H); 13C NMR (125 MHz, 
D2O) δ 174.8, 174.5, 162.7, 158.4, 117.8, 114.9, 86.3, 75.5, 72.0, 68.2, 62.5, 52.1, 50.8, 39.7, 38.2, 
29.5, 29.2, 28.2, 27.6, 27.1, 22.0. ESI-HRMS calcd for C18H35N4O7S2: 483.1946, found: m/z 
483.1947 [M + H]+. 
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General Protocol for the synthesis of oligoethylene glycol dibromide 
  
 
 
 
 
 
 
Scheme 2. Synthesis of oligoethylene glycol dibromides. Reagent and conditions i) MsCl/Py; 
ii) LiBr/Acetone. 
 
To a solution of the diol (1.0 eq) in pyridine, methanesulfonyl chloride (3.0 eq) was added 
dropwise at 0C. The reaction mixture was stirred at room temperature for 3 h. The reaction was 
washed with HCl (1 M) and NaHCO3 (aq), extracted with CH2Cl2 and dried with Na2SO4. The 
solvent was removed in vacuo and the residue was dissolved in acetone. Lithium bromide (4 eq) 
was added. The reaction mixture was stirred and heated up to reflux overnight. The reaction was 
concentrated in vacuo and the crude product was purified by chromatography to obtain the 
product.   
 
Tetraethylene glycol dibromide (m=2) was prepared by the procedure described above as 
a yellow oil (87%).1H NMR (400 MHz, CDCl3) δ 3.81 (t, J = 6.0 Hz, 4H, BrCH2 CH2O), 3.67 (s, 
HOCH2CH2(OCH2CH2)mOCH2CH2OH
i) MsCl/Py
ii) LiBr/Acetone
BrCH2CH2(OCH2CH2)mOCH2CH2Br
m=2, 3, 4 m=2, 3, 4
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8H, OCH2CH2O), 3.48 (t, J = 6.0 Hz, 4H, BrCH2CH2O); 13C NMR (101 MHz, CDCl3) δ 71.2, 70.7, 
70.5, 30.4. 
 
Pentaethylene glycol dibromide (m=3) was prepared by the procedure described above as 
a yellow oil (85%).1H NMR (400 MHz, CDCl3) δ 3.81 (t, J = 6.0 Hz, 4H, BrCH2 CH2O), 3.67 (s, 
12H, OCH2CH2O), 3.48 (t, J = 6.0 Hz, 4H, BrCH2CH2O); 13C NMR (101 MHz, CDCl3) δ 71.2, 
70.7, 70.6, 70.5, 30.4. 
 
Hexaethylene glycol dibromide (m=4) was prepared by the procedure described above as 
a yellow oil (85%).1H NMR (400 MHz, CDCl3) δ 3.80 (t, J = 6.0 Hz, 4H, BrCH2 CH2O), 3.67 (s, 
16H, OCH2CH2O), 3.45 (t, J = 6.4 Hz, 4H, BrCH2CH2O); 13C NMR (101 MHz, CDCl3) δ 71.2, 70.7, 
70.6, 70.5, 30.4. 
 
b. Synthesis of S-sialodimers. 
 
General Protocol for the synthesis of S-sialodimers. 
 
Thioacetate 3 (2.2 eq) and dibromide (1eq) were dissolved in dry DMF. DEA was added 
dropwise and the reaction was stirred for 3 h at room temperature. Then the reaction mixture 
was washed with 1 M HCl (aq), extracted with CH2Cl2, dried with Na2SO4. The solution was 
concentrated and purified by column chromatography.  
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1, 6-Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy-D-
glycero-α-D-galacto-non-2-ulopyranosyl) onate]-hexane 8. Thioacetate 3 and 1, 6- 
dibromohexane were used as described above. The crude product was purified by column 
chromatography to give the title compound as colorless oil (86%). 1H NMR (400 MHz, CDCl3) δ 
5.74 (d, J = 8.3 Hz, 2H, -NHAc), 5.32-5.28 (m, 4H, H-7, H-8), 4.30 (d, J = 12.4 Hz, 2H, H-9a), 
4.17 (dd, J = 12.4, 4.0 Hz, 2H, H-9b), 4.06 (d, J = 10.5 Hz, 2H, H-6), 3.91-3.90 (m, 2H, H-4), 
3.80 (s, 6H, -OMe), 3.35-3.34 (m, 2H, H-5), 2.76-2.73 (m, 4H, -SCHa-, H3eq), 2.62 – 2.42 (m, 
2H, -SCHb-), 2.34 – 1.90 (m, 24H, -OAc), 1.75 (t, J = 12.6 Hz, 2H, H-3ax), 1.37 (dd, J = 53.7, 
48.4 Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 170.80, 170.73, 170.60, 170.00, 168.31, 82.97, 77.37, 
77.05, 76.74, 72.69, 68.42, 67.77, 62.04, 57.77, 52.93, 51.68, 38.22, 29.10, 28.78, 28.35, 23.47, 
21.12, 20.92, 20.73. 
 
1, 12-Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy-D-
glycero-α-D-galacto-non-2-ulopyranosyl) onate]-dodecane 9. Thioacetate 3 and 1, 12- 
dibromo dodecane were used as described above. The crude product was purified by column 
chromatography to give the title compound as colorless oil (76%). 1H NMR (400 MHz, CDCl3) δ 
5.86 (br, 2H, -NHAc), 5.31-5.28 (m, 4H, H-7, H-8), 4.30 (dd, J = 12.4, 2.0 Hz, 2H, H-9a), 4.17 
(d, J = 12.4 Hz, 2H, H-9b ), 4.02 (d, J = 6.4 Hz, 2H, H-6), 3.92-3.79 (m, 2H, H-4), 3.79 (s, 6H, -
OMe), 3.36-3.34 (m, 2H, H-5), 2.78-2.71 (m, 4H, -SCHa-, H3eq), 2.57-2.52 (m, 2H, -SCHa-), 2.29 
– 1.90 (m, 24H), 1.75 (t, J = 12.5 Hz, 1H, H3ax ), 1.58 – 1.18 (m, 20H); 13C NMR (101 MHz, CDCl3) 
δ 170.82, 170.62, 170.03, 168.35, 83.00, 77.38, 77.07, 76.75, 72.87, 68.55, 67.76, 62.05, 57.94, 
53.45, 52.91, 51.46, 38.20, 29.54, 29.45, 29.26, 29.19, 28.90, 28.76, 23.44, 21.12, 20.91, 20.74. 
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy-D-glycero-α-
D-galacto-non-2-ulopyranosyl) onate]-tetraethylene glycol 10. Thioacetate 3 and 
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tetraethylene glycol dibromide were used as described above. The crude product was purified by 
column chromatography to give the title compound as colorless oil (80%). 1H NMR (400 MHz, 
CDCl3) δ 5.86 (br, 2H, -NHAc), 5.31-5.28 (m, 4H, H-7, H-8), 4.29 (d, J = 12.4 Hz, 2H, H-9a), 
4.23 – 4.09 (m, 2H, H-9b), 4.03 (d, J = 10.4 Hz, 2H, H-6 ), 3.89-3.85 (m, 2H, H-4), 3.80 (s, 6H, 
OMe), 3.61-3.50 (m, 12H), 3.37-3.36 (m, 2H, H-5), 3.05 – 2.87 (m, 2H, -SCHa-), 2.86 – 2.70 (m, 
4H, m, 4H, -SCHb-, H3eq), 2.39 – 1.89 (m, 24H), 1.77 (t, J = 12.6 Hz, 2H, H3ax); 13C NMR (101 
MHz, CDCl3) δ 170.87, 170.65, 170.12, 168.36, 82.78, 77.39, 77.07, 76.75, 72.82, 70.44, 70.24, 
68.35, 67.69, 62.09, 57.80, 53.05, 51.54, 38.09, 28.93, 23.43, 21.12, 20.90, 20.72. 
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy-D-
glycero-α-D-galacto-non-2-ulopyranosyl) onate]-pentaethylene glycol 11. Thioacetate 
3 and pentaethylene glycol dibromide were used as described above. The crude product was 
purified by column chromatography to give the title compound as colorless oil (87%).1H NMR 
(400 MHz, CDCl3) δ 5.81 (d, J = 8.3 Hz, 2H, -NHAc), 5.29-5.27 (m, 4H, H-7, H-8), 4.30 (d, J = 
12.3 Hz, 2H, H-9a), 4.14 (dd, J = 12.4, 4.2 Hz, 2H, H-9b), 4.05 (d, J = 10.5 Hz, 2H, H-6), 3.98 – 
3.87 (m, 2H, H-4), 3.86 – 3.77 (m, 8H, H-6, OMe), 3.61-3.60 (m, 16H), 3.32 (d, J = 9.3 Hz, 2H, 
H-5), 3.05 – 2.87 (m, 2H, -SCHa-), 2.86 – 2.70 (m, 4H, m, 4H, -SCHb-, H3eq), 2.39 – 1.89 (m, 
24H), 1.77 (t, J = 12.6 Hz, 2H, H3ax); 13C NMR (101 MHz, CDCl3) δ 170.74, 170.62, 170.48, 
169.98, 168.41, 82.84, 77.35, 77.03, 76.71, 72.82, 70.57, 70.43, 70.24, 68.50, 67.87, 62.11, 57.69, 
52.92, 51.78, 38.20, 28.99, 23.35, 21.01, 20.80, 20.60. 
 
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-4-azido-3, 4, 5-trideoxy-D-glycero-α-
D-galacto-non-2-ulopyranosyl) onate]-hexaethylene glycol 12. Thioacetate 3 and 
hexaethylene glycol dibromide were used as described above. The crude product was purified by 
131 
 
 
column chromatography to give the title compound as colorless oil (85%).1H NMR (400 MHz, 
CDCl3) δ 5.88 (s, br, 2H, -NHAc), 5.29-5.27 (m, 4H, H-7, H-8), 4.27 (d, J = 12.0 Hz, 2H, H-9a), 
4.13 (d, J = 9.6 Hz, 2H, H-9b), 4.00 (d, J = 9.3 Hz, 2H, H-4), 3.83-3.78 (M, 8H, H-6, OMe), 
3.61-3.60 (m, 20H), 3.38-3.37 (m, 2H, H-5), 3.03 – 2.85 (m, 2H, -SCHa-), 2.85 – 2.65 (m, 4H, -
SCHb-, H3eq), 2.36 – 1.88 (m, 24H), 1.75 (t, J = 12.6 Hz, 1H, H-3ax ); 13C NMR (101 MHz, CDCl3) 
δ 170.83, 170.62, 170.05, 168.33, 82.73, 77.41, 77.09, 76.77, 72.82, 70.55, 70.52, 70.39, 70.21, 
68.24, 67.63, 62.07, 57.82, 53.47, 53.02, 51.42, 38.09, 28.93, 23.42, 21.12, 20.90, 20.72. 
 
General protocol for the deprotection of the azide. 
The azide compound was treated with MeOH and 1 M NaOH (1:1 v/v). After stirred for 1 h, the 
solution was neutralized to pH 7 with Dowex 50W X 8 (H+) resin, filtered and evaporated to 
dryness. Then the residue in EtOH/EtOAc (1:1) with 2 drop of acetic acid was hydrogenated with 
Pd(OH)2/C under atmosphere of hydrogen (3 psi) for 12 h. Then the mixture was filtered and 
washed with MeOH. The filtrate was concentrated to dryness, purified by Bio-Gel® (P-2 
Polyacrylamide Gel column) and lyophilized to get a colorless amorphous solid. 
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Scheme 2. Synthesis of bivalent analogs of S-Sialosides. Reagents and Conditions: a) DEA, 
DMF; 76-85%; b) i) NaOH/CH3OH (aq), ii) H2/Pd(OH)2; 90-92% % over 2 steps; c) i) 
H2/Pd(OH)2, ii)MeS-(C=NBoc)NHBoc, HgCl2, TEA, CH2Cl2. 85-89% % over 2 steps; d) 
NaOH/CH3OH (aq), 1 h; i) TFA/DCM (1:1), 80-85% over 2 steps.  
 
1, 6-Di-S-[5-acetamido- -4-amino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2-
enonic acid]-hexane C6-SA. 1H NMR (500 MHz, D2O) δ 3.89-3.47 (m, 14H), 2.78-2.63 (m, 
4H, -SCHa-, H3eq), 2.58 – 2.53 (m, 2H, -SCHb-), 1.94 (s, 6H, -NHAc), 1.46-1.24 (m, 8H); 13C 
NMR (125 MHz, D2O) δ 174.5, 174.3, 170.4, 83.0, 74.3, 70.3, 67.5, 67.3, 62.3, 58.3, 53.1, 49.3, 
36.8, 28.5, 28.1, 26.9, 21.6, 21.5. ESI-HRMS calcd for C28H51N4O14S2: 730.2843, found: m/z 730. 
2868 [M + H]+. 
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1, 12-Di-S-[5-acetamido- -4-amino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2-
enonic acid]-dodecane C12SA. 1H NMR (500 MHz, D2O) δ 3.90-3.74 (m, 14H), 2.71-2.61 
(m, 4H, -SCHa-, H3eq), 2.58 – 2.53 (m, 2H, -SCHb-), 1.95 (s, 6H, -NHAc), 1.73-1.71 (m, 1H, H3ax) 
1.49-1.07 (m, 20H); 13C NMR (125 MHz, D2O) δ 174.2, 172.4, 84.3, 74.4, 71.0, 67.4, 67.2, 62.3, 
61.9, 58.9, 49.4, 37.5, 28.9, 28.7, 28.4, 28.1, 21.6. ESI-HRMS calcd for C34H51N4O14S2: 815.3782, 
found: m/z 815.3787 [M + H]+. 
 
 
Di-S-[5-acetamido--4-amino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2-enonic 
acid]-tetraethylene glycol TetraEG-SA. 1H NMR (500 MHz, D2O) δ 3.76-3.48 (m, 26H), 
2.85-2.78 (m, 6H, -SCH2-, H3eq), 1.93 (s, 6H, -NHAc), 1.87-1.85 (m, 1H, H3ax); 13C NMR (125 
MHz, D2O) δ 174.5, 172.4, 84.9, 74.1, 71.4, 69.2, 68.9, 68.8, 67.2, 62.1, 61.9, 50.3, 46.9, 36.1, 
28.5, 21.6, 21.5. ESI-HRMS calcd for C30H55N4O17S2: 807.3004, found: m/z 807.3022 [M + H]+. 
 
Di-S-[5-acetamido-4-amino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2-enonic 
acid]-pentaethylene glycol PentaEG-SA. 1H NMR (500 MHz, D2O) δ 3.76-3.48 (m, 30H), 
2.85-2.78 (m, 6H, -SCH2-, H3eq), 1.93 (s, 6H, -NHAc), 1.87-1.85 (m, 1H, H3ax); 13C NMR (125 
MHz, D2O) δ 174.5, 174.2, 173.2, 172.5, 85.4, 85.0, 74.4, 74.1, 71.5, 71.4, 69.3, 69.2, 69.1, 68.9, 
68.8, 68.4, 67.4, 67.3, 67.2, 66.1, 62.0, 61.9, 59.3, 50.3, 49.2, 47.0, 37.4, 36.1, 28.5, 21.6, 21.5. 
ESI-HRMS calcd for C32H59N4O18S2: 851.3266, found: m/z 851.3258 [M + H]+. 
 
Di-S-[5-acetamido-4-amino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2-enonic 
acid]-hexaethylene glycol HexaEG-SA. 1H NMR (500 MHz, D2O) δ 3.76-3.41 (m, 34 H), 
2.85-2.71 (m, 6H, -SCH2-, H3eq), 1.93 (s, 6H, -NHAc), 1.71-1.69 (m, H3ax); 13C NMR (125 MHz, 
D2O) δ 174.5, 174.2, 173.2, 85.4, 74.1, 71.4, 69.4, 69.1, 68.9, 68.7, 68.4, 67.4, 66.1, 62.0, 59.4, 
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50.3, 49.2, 37.5, 28.5, 22.7, 21.5, 21.5. ESI-HRMS calcd for C34H63N4O19S2: 895.3528, found: m/z 
895.3521 [M + H]+. 
 
General protocol for the changing of the azide to guanidine. 
 
The azide in EtOH/EtOAc (1:1) was hydrogenated with Pd(OH)2/C under atmosphere of 
hydrogen (3 psi) for 12 h. Then the mixture was filtered and washed with MeOH. The filtrate 
was concentrated to dryness. The guanidine compound was synthesized according to the 
procedure described above for the synthesis of the monoer guanidino product as colorless syrup 
(85-89%). 
 
1, 6-Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) onate]-
hexane 13. 1H NMR (400 MHz, CDCl3) δ 11.30 (s, 2H, -NHBoc), 8.39 (d, J = 7.1 Hz, 2H, -
NHBoc ), 6.03 (d, J = 8.7 Hz, 2H, -NHAc), 5.36-5.29 (m, 4H, H-7, H-8), 4.35 (d, J = 12.3 Hz, 1H, 
H-9a), 4.12-3.99 (m, 6H, H-9b, H-4, H-5), 3.95 – 3.67 (m, 8H, OMe, H-6), 2.81 – 2.70 (m, 4H, -
SCHa-, H3eq ), 2.67 – 2.47 (m, 2H, -SCHb-), 2.16, 2.14, 2.04, 1.83 (4s, 24H, -Ac ), 1.69 – 1.14 (m, 
34H).13C NMR (101 MHz, CDCl3) δ 170.81, 170.65, 170.13, 168.79, 162.99, 156.79, 152.70, 83.81, 
83.36, 79.50, 77.35, 77.03, 76.71, 75.46, 69.19, 67.83, 62.35, 52.89, 50.46, 49.69, 38.82, 29.69, 
29.09, 28.83, 28.43, 28.26, 28.02, 23.02, 21.21, 20.98, 20.81. 
 
 
1, 12-Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-
tert-butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) 
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onate]-dodecane 14. 1H NMR (400 MHz, CDCl3) δ 11.30 ((s, 2H, -NHBoc), 8.39 (d, J = 7.2 
Hz, 2H, -NHBoc), 6.05 (d, J = 9.1 Hz, 2H, -NHAc), 5.63 – 5.16 (m, 4H, H-7, H-8 ), 4.35 (dd, J = 
12.4, 2.6 Hz, 1H, H-9a), 4.12-3.99 (m, 6H, H-9b, H-4, H-5), 3.95 – 3.70 (m, 8H, OMe, H-6), 2.81 
– 2.70 (m, 4H, -SCHa-, H3eq ), 2.67 – 2.47 (m, 2H, -SCHb-), 2.18, 2.16, 2.03, 1.82 (4s, 24H, -Ac), 
1.68 – 1.19 (m, 56H); 13C NMR (101 MHz, CDCl3) δ 170.81, 170.65, 170.17, 168.81, 162.98, 
156.79, 152.70, 83.80, 83.38, 79.49, 77.36, 77.04, 76.73, 75.51, 69.32, 67.88, 62.35, 52.85, 50.47, 
49.69, 38.84, 29.61, 29.51, 29.27, 28.95, 28.85, 28.25, 28.02, 23.02, 21.20, 20.96, 20.80. 
 
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) onate]-
tetraethylene glycol 15. 1H NMR (400 MHz, CDCl3) δ 11.31 (s, 2H, -NHBoc), 8.40 (d, J = 6.8 
Hz, 2H, -NHBoc), 6.06 (d, J = 8.6 Hz, 2H, -NHAc), 5.35-5.27 (m, 4H, H-7, H-8), 4.33 (d, J = 
12.3 Hz, 2H, H-6), 4.21 – 3.95 (m, 6H, H-9a, H-9b, H-4), 3.85 (s, 6H, -OMe), 3.76 (d, J = 9.9 
Hz, 1H, H-5), 3.67-3.63 (m, 12H), 3.03-2.82 (m, 6H, -SCHa-, H3eq-SCHb-), 2.18, 2.17, 2.04, 1.89 
(4s, 12H, -Ac), 1.90-1.87 (m, 1H, H-3ax), 1.49 (s, 36H); 13C NMR (101 MHz, CDCl3) δ 170.82, 
170.19, 168.78, 162.97, 156.81, 152.70, 83.84, 83.15, 79.53, 77.35, 77.03, 76.71, 75.47, 70.45, 
70.30, 70.22, 68.98, 67.76, 62.41, 52.97, 50.42, 49.63, 38.73, 30.92, 28.93, 28.26, 28.03, 23.02, 
21.22, 20.98, 20.80. 
 
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) onate]-
pentaethylene glycol 16. 1H NMR (400 MHz, CDCl3) δ 11.28 (s, 2H, -NHBoc), 8.38 (d, J = 
6.8 Hz, 2H, -NHBoc), 6.06 (d, J = 8.6 Hz, 2H, -NHAc), 5.34-5.26 (m, 4H, H-7, H-8), 4.33 (d, J = 
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12.3 Hz, 2H, H-6), 4.07 – 3.97 (m, 6H, H-9a, H-9b, H-4), 3.81 (s, 6H, -OMe), 3.76-3.73 (d, J = 
9.9 Hz, 1H, H-5), 3.63-3.61 (m, 16H), 2.94-2.82 (m, 6H, -SCHa-, H3eq, -SCHb-), 2.18, 2.17, 2.04, 
1.89 (4s, 12H, -Ac), 1.90-1.87 (m, 1H, H-3ax), 1.49 (s, 36H); 13C NMR (125 MHz, CDCl3) δ 170.3, 
170.2, 169.7, 169.6, 168.3, 162.4, 156.3, 152.1, 83.3, 82.6, 79.1, 74.9, 70.0, 69.9, 69.8, 69.7, 68.4, 
67.2, 61.9, 52.3, 49.8, 49.1, 38.1, 28.4, 27.7, 27.5, 22.5, 20.7, 20.4, 20.3,   
 
Di-S-[Methyl 5-acetamido-7, 8, 9-tri-O- acetyl-3, 4, 5-trideoxy-4-(bis-N, N'-tert-
butyloxycarbonyl)-guanidino-D-glycero-α-D-galacto-non-2-ulopyranosyl) onate]-
hexaethylene glycol 17.1H NMR (400 MHz, CDCl3) δ 11.29 (s, 2H, -NHBoc), 8.39 (d, J = 6.8 
Hz, 2H, -NHBoc), 6.05 (d, J = 8.8 Hz, 2H, -NHAc), 5.35-5.26 (m, 4H, H-7, H-8), 4.33 (d, J = 
12.3 Hz, 2H, H-6), 4.09 – 3.98 (m, 6H, H-9a, H-9b, H-4), 3.82 (s, 6H, -OMe), 3.77-3.74 (d, J = 
9.9 Hz, 1H, H-5), 3.64-3.62 (m, 20H), 2.95-2.78 (m, 6H, -SCHa-, H3eq, -SCHb-), 2.15, 2.13, 2.03, 
1.83 (4s, 12H, -Ac), 1.90-1.87 (m, 1H, H-3ax), 1.48 (s, 36H);13C NMR (101 MHz, CDCl3) δ 170.8, 
170.7, 170.2, 168.8, 162.9, 156.8, 152.6, 83.8, 83.1, 79.5, 77.3, 77.0, 76.7, 75.4, 70.5, 70.4, 70.2, 
70.2, 68.9, 67.7, 62.4, 52.9, 50.3, 49.6, 38.7, 28.9, 28.2, 28.0, 23.0, 21.2, 20.9, 20.7. 
 
General protocol for the deprotection of the guanidine. 
 
The guanidine compound was treated with MeOH and 1 M NaOH. After stirred for 1 h, the 
solution was neutralized to pH 7 with Dowex 50W X 8 (H+) resin, filtered and evaporated to 
dryness. Then TFA/DCM (1:1) was added, and the reaction mixture was stirred for 2 h at room 
temperature. The solution was evaporated to dryness. The residue was purified by Bio-Gel® (P-2 
Polyacrylamide Gel column) and lyophilized to get a colorless amorphous solid. 
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1, 6-Di-S-[5-acetamido- -4-guanidino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2- 
enonic acid]-hexane C6-SG. 1H NMR (500 MHz, D2O) δ 3.90-3.49 (m, 14H), 2.68-2.62 (m, 
4H, -SCHa-, H3eq), 2.58 – 2.54 (m, 2H, -SCHb-), 1.88 (s, 6H, -NHAc), 1.79 (t, J= 10, 15 Hz, H3ax), 
1.46-1.24 (m, 8H); 13C NMR (125 MHz, D2O) δ 174.5, 172.8, 162.3, 156.1, 84.7, 74.3, 71.2, 67.4, 
51.4, 49.3, 37.8, 29.0, 28.5, 28.9, 28.4, 27.0, 21.3. ESI-HRMS calcd for C30H55N8O14S2: 815.3279, 
found: m/z 815.3282 [M + H]+. 
 
1, 12-Di-S-[5-acetamido- -4- guanidino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-
2- enonic acid]-dodecane C12-SG. 1H NMR (500 MHz, D2O) δ 3.95-3.55 (m, 14H), 2.69-
2.57 (m, 6H, -SCHa-, H3eq, SCHb-), 1.90 (s, 6H, -NHAc), 1.49-1.07 (m, 20H); 13C NMR (125 MHz, 
D2O) δ 174.1, 170.0, 162.5, 162.2, 156.2, 117.0, 114.7, 85.4, 82.7, 74.5, 70.4, 67.6, 62.2, 53.2, 50.4, 
49.5, 37.3, 29.0, 28.9, 28.6, 28.4, 28.1, 21.4. ESI-HRMS calcd for C36H67N8O14S2: 899.4218, 
found: m/z 899.4221 [M + H]+. 
 
Di-S-[5-acetamido--4-guanidino-3,4, 5-trideoxy-D-glycero-α-D-galacto-non-2- 
enonic acid]-tetraethylene glycol  TetraEG-SG). 1H NMR (500 MHz, D2O) δ 3.87-3.48 
(m, 26H), 2.85-2.78 (m, 6H, -SCH2-, H3eq), 1.93 (s, 6H, -NHAc), 1.77 (t, J= 10, 15 Hz, H3ax), 13C 
NMR (125 MHz, D2O) δ 173.9, 173.0, 156.2, 85.0, 74.4, 71.4, 69.3, 69.0, 68.9, 68.8, 67.4, 61.9, 
51.5, 49.4, 37.8, 28.3, 21.3. ESI-HRMS calcd for C32H59N8O17S2: 891.9843, found: m/z 815.9832 
[M + H]+. 
 
Di-S-[5-acetamido-4-guanidino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2- 
enonic acid]-pentaethylene glycol PentaEG-SG. 1H NMR (500 MHz, D2O) δ 3.90-3.51 
(m, 30H), 2.85-2.68 (m, 6H, -SCH2-, H3eq), 1.93 (s, 6H, -NHAc), 1.79 (1.79 (t, J= 10, 15 Hz, 
H3ax),); 13C NMR (125 MHz, D2O) δ 173.9, 173.1, 156.1, 85.0, 74.4, 71.4, 69.3, 69.0, 68.9, 68.8, 
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67.4, 61.9, 51.5, 49.4, 37.8, 28.4, 21.3. ESI-HRMS calcd for C34H63N8O18S2: 925.3702, found: m/z 
815.3701 [M + H]+. 
 
Di-S-[5-acetamido-4-guanidino-3, 4, 5-trideoxy-D-glycero-α-D-galacto-non-2- 
enonic acid]-hexaethylene glycol HexaEG-SG. 1H NMR (500 MHz, D2O) δ 3.89-3.48 (m, 
34 H), 2.84-2.68 (m, 6H, -SCH2-, H3eq), 1.88 (s, 6H, -NHAc), 1.77 1.79 (t, J= 10, 15 Hz, H3ax); 13C 
NMR (125 MHz, D2O) δ 173.9, 173.3, 156.1, 85.4, 74.1, 71.5, 69.4, 69.1, 68.9, 68.7, 67.4, 61.9, 
51.7, 49.4, 37.9, 28.4, 21.3. ESI-HRMS calcd for C36H66N8O19S2: 979.3964, found: m/z 979.3976 
[M + H]+. 
 
To a stirring solution of compound 1 (1.1 g, 8.0mmol) in tetrahydrofurane (THF), 2-
chloro-4,6-dimethoxy-1,3,5-triazine (1.5 g, 8.7mmol) and 4-methylmorpholine (0.885 g, 
8.7mmol) was added.  Reaction mixture was placed in an ice bath and allowed to stir 
overnight.  Compound 2 was dissolved in THF with 4-methylmorpholine (0.482 g, 
8.7mmol) was added into the reaction mixture dropwise at 0oC.  The reaction mixture 
was allowed to stir overnight.  The reaction was quenched with water, extracted with 
ethyl acetate (3x), dried over sodium sulfate and concentrate invacuo.  Compound was 
purified using flash chromatography with solvent system of hexane and acetone (10:1 
ratio) to yield a golden yellow solid compound 2 (90% yield).1H NMR (400 MHz, CDCl3) 
δ 6.15 (s, 1H), 6.11 (s, 1H), 6.03 (s, 1H), 4.12 – 4.01 (m, 2H), 2.94 (d, J = 11.3 Hz, 2H), 
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2.27 – 2.19 (m, 1H), 2.03 (dd, J = 8.5, 4.3 Hz, 1H), 1.93 (dd, J = 7.8, 3.2 Hz, 1H), 1.71 (d, 
J = 7.8 Hz, 1H), 1.41 – 1.28 (m, 2H).13C NMR (101 MHz, CDCl3) δ 175.4, 138.3, 135.9, 
79.9, 71.4, 47.1, 46.3, 44.1, 41.6, 30.5, 29.3.  HRMS (ESI) Calculated for C11H13NO 
175.0997, found:  176.1064 (M+H).   
 
 
To a stirring solution of compound 3(220 mg, 0.32mmol)in THF, water and t-butyl 
alcohol mixture (1:1:1 ratio), then compound 2(50.0 mg, 0.29mmol) was added.  Copper 
sulfate (87 mg, 0.34mmol) was added along with sodium ascorbate (67 mg, 0.34) and 
argon as was bubbled through for 10 minutes then the reaction was allowed to stir over 
night at room temperature.  Solvent were removed via vacuo and product were purified 
using flash column chromatography with hexane:acetone (2:1 ratio) solvent system to 
yield desired product, 150 mg (57% yield).1H NMR (400 MHz, CDCl3) δ 6.04 (d, J = 13.5 
Hz, 1H), 5.88 (d, J = 9.6 Hz, 1H), 5.32 (s, 1H), 5.28 (s, 1H), 5.07 (d, J = 8.9 Hz, 1H), 4.37 
(s, 1H), 4.28 (d, J = 12.2 Hz, 1H), 4.06 (s, 1H), 3.85 (s, 1H), 3.75 (d, J = 15.5 Hz, 2H), 
3.52 (d, J = 9.6 Hz, 1H), 2.89 (d, J = 11.7 Hz, 1H), 2.75 – 2.64 (m, 1H), 2.61 (s, 1H), 2.47 
(dd, J = 12.5, 6.9 Hz, 1H), 2.12 (s, 1H), 2.05 (s, 1H), 1.99 (s, 2H), 1.86 (s, 2H), 1.75 (t, J = 
12.6 Hz, 1H), 1.65 (s, 1H), 1.53 – 1.42 (m, 1H), 1.36 (s, 5H), 1.23 (s, 1H).13C NMR (101 
MHz, CDCl3) δ 171.0, 170.7, 170.0, 169.9, 168.7, 156.1, 137.2, 135.2, 83.5, 79.8, 77.5, 77.1, 
76.8, 74.7, 68.5, 67.6, 62.3, 53.5, 52.9, 50.2, 49.9, 47.1, 46.2, 41.57, 39.1, 30.5, 29.8, 29.3, 
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28.9, 28.6, 28.3, 27.9, 26.0, 23.1, 21.2, 20.8.  HRMS (ESI) Calculated for C40H60N6O13S 
864.3939, found 865.3996 (M+H). 
 
 
To a stirring solution of compound 3(220 mg, 0.22mmol)in THF, water and t-butyl 
alcohol mixture (1:1:1 ratio), then compound 2(34.8 mg, 0.20mmol) was added.  Copper 
sulfate (35.1 mg, 0.22mmol) was added along with sodium ascorbate (43.0 mg, 0.22) 
and argon as was bubbled through for 10 minutes then the reaction was allowed to stir 
over night at room temperature.  Solvent were removed via vacuo and product were 
purified using flash column chromatography with hexane:acetone (2:1 ratio) solvent 
system to yield compound 4, 150 mg. 
1H NMR (400 MHz, CDCl3) δ 11.26 (s, 1H), 8.34 (d, J = 6.6 Hz, 1H), 6.18 – 5.96 (m, 3H), 
5.28 (dt, J = 18.0, 6.0 Hz, 3H), 4.48 (s, 1H), 4.28 (d, J = 12.4 Hz, 3H), 4.07 – 3.91 (m, 
3H), 3.77 (s, 4H), 2.86 (d, J = 7.0 Hz, 2H), 2.80 – 2.73 (m, 1H), 2.73 – 2.64 (m, 1H), 
2.59 (s, 1H), 2.51 – 2.42 (m, 1H), 2.13 (s, 1H), 2.11 (s, 3H), 2.08 (s, 3H), 2.02 (s, 1H), 1.97 
(s, 3H), 1.84 (d, J = 10.1 Hz, 3H), 1.78 (s, 2H), 1.62 (t, J = 12.6 Hz, 1H), 1.43 (d, J = 2.1 
Hz, 20H), 1.39 – 1.33 (m, 3H), 1.28 (d, J = 5.1 Hz, 4H).  13C NMR (100 MHz, CDCl3) δ 
170.6, 170.5, 169.9, 168.6, 162.8, 156.5, 152.5, 137.9, 135.9, 83.6, 83.1, 79.2, 77.3, 77.0, 
76.7, 75.1, 68.6, 67.5, 62.2, 52.7, 50.3, 50.0, 49.6, 46.9, 46.1, 44.2, 41.3, 38.6, 34.8, 30.3, 
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29.8, 29.1, 28.8, 28.4, 28.1, 27.8, 25.8, 22.8, 21.0, 20.8, 20.6.  HRMS (ESI) Calculated 
for C46H70N8O15S 1006.4681, found:  504.2402 (1/2M+1). 
 
General Procedures for Polymerization 
To a stirring solution of monomer 4 (150 mg, 0.17 mmol) in anhydrous THF at rt, 
Grubbs catalyst II (2.9 mg, 0.003 mmol) and reaction mixture was allowed to stirred 
overnight.  Reaction was monitored with thin layer chromatography until starting 
materials has all gone.  After the starting materials are gone, the reaction was quenched 
with vinyl ethyl ether (0.1 ml) and allowed to stir for 30 minutes then hexane (10 mL) 
was added to the reaction mixture.  The solid was filtered and wasted with hexane:THF 
(10:1 ratio, 3x) to yield a grayish tan solid.   
Polymer Type I (NHBoc) 
5:1 (Ratio) 
1H NMR (400 MHz, CDCl3) δ 7.68 (s, 1H), 5.93 (s, 1H), 5.26 (d, J = 75.7 Hz, 5H), 4.31 (d, 
J = 10.7 Hz, 4H), 4.11 (s, 2H), 3.93 – 3.64 (m, 7H), 3.56 (s, 2H), 2.71 (s, 3H), 2.53 (s, 
3H), 2.24 – 2.01 (m, 11H), 1.98 – 1.75 (m, 10H), 1.34 (d, J = 46.0 Hz, 20H).  13C NMR 
(101 MHz, CDCl3) δ 171.1, 170.7, 170.1, 170.0, 168.8, 156.1, 83.5, 79.8, 74.8, 68.6, 68.0, 
67.6, 62.3, 53.0, 50.2, 50.0, 39.1, 34.7, 34.5, 31.6, 30.1, 29.1, 28.6, 28.3, 28.1, 26.0, 25.6, 
25.3, 23.2, 22.7, 21.2, 20.9, 20.7, 18.8, 14.1, 11.4. 
10:1 (Ratio) 
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1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 5.97 (s, 1H), 5.36 (s, 2H), 5.18 (s, 1H), 4.32 (d, 
J = 11.7 Hz, 3H), 4.10 (d, J = 10.7 Hz, 1H), 3.81 (dt, J = 9.0, 7.9 Hz, 6H), 3.58 (s, 1H), 
2.72 (s, 4H), 2.23 – 1.76 (m, 14H), 1.34 (d, J = 52.1 Hz, 11H).13C NMR (101 MHz, CDCl3) 
δ 171.1, 170.7, 170.1, 170.0, 168.8, 156.1, 83.5, 79.8, 74.8, 74.0, 68.6, 68.0, 67.6, 62.3, 
53.0, 50.2, 39.1, 34.8, 30.1, 29.0, 28.6, 28.3, 28.1, 26.0, 25.6, 23.2, 21.3, 20.9.   
25:1 (Ratio) 
1H NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 5.98 (s, 1H), 5.36 (s, 3H), 5.18 (s, 2H), 4.31 
(d, J = 11.4 Hz, 5H), 4.09 (d, J = 10.4 Hz, 1H), 3.90 (d, J = 9.2 Hz, 1H), 3.77 (d, J = 6.6 
Hz, 4H), 3.57 (s, 1H), 2.68 (d, J = 26.2 Hz, 3H), 2.48 (d, J = 37.9 Hz, 2H), 2.21 – 1.98 
(m, 10H), 1.88 (d, J = 12.3 Hz, 6H), 1.62 – 1.47 (m, 3H), 1.47 – 1.25 (m, 18H).13C NMR 
(101 MHz, CDCl3) δ 171.1, 170.74, 170.1, 170.0, 168.8, 156.1, 83.5, 79.8, 74.8, 68.6, 68.0, 
67.6, 62.3, 53.0, 50.2, 50.0, 39.1, 34.7, 34.5, 31.6, 30.1, 29.1, 28.6, 28.3, 28.1, 26.0, 25.6, 
25.3, 23.2, 22.7, 21.2, 20.9, 20.7, 18.8, 14.1, 11.4. 
 
Polymer Type II (NHC=NBocNHBoc) 
5:1 (Ratio) 
1H NMR (400 MHz, CDCl3) δ 11.31 (s, 4H), 8.39 (d, J = 6.2 Hz, 4H), 7.63 (s, 3H), 6.14 (s, 
4H), 5.33 (d, J = 13.8 Hz, 13H), 4.32 (s, 13H), 4.18 – 3.94 (m, 13H), 3.83 (s, 8H), 3.75 (t, 
J = 6.4 Hz, 11H), 2.15 (d, J = 10.4 Hz, 28H), 2.03 (s, 11H), 1.93 – 1.80 (m, 32H), 1.46 (d, 
J = 20.7 Hz, 71H), 1.36 – 1.23 (m, 63H), 0.98 (s, 13H), 0.93 – 0.82 (m, 55H).  13C NMR 
(101 MHz, CDCl3) δ 170.8, 170.7, 170.2, 168.7, 163.0, 156.7, 152.7, 83.8, 83.3, 79.5, 75.3, 
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68.9, 68.0, 67.8, 62.4, 52.9, 50.3, 49.7, 38.8, 36.1, 34.7, 31.6, 29.1, 28.3, 28.0, 25.6, 25.3, 
22.6, 20.6, 18.8, 14.1, 11.4. 
10:1 (Ratio) 
1H NMR (400 MHz, CDCl3) δ 11.30 (s, 10H), 8.38 (d, J = 6.5 Hz, 10H), 7.60 (d, J = 28.2 
Hz, 10H), 6.16 (s, 10H), 5.32 (t, J = 10.0 Hz, 30H), 5.18 (s, 10H), 4.32 (d, J = 10.0 Hz, 
50H), 4.11 – 3.95 (m, 20H), 3.82 (s, 10H), 3.74 (s, 45H), 2.14 (d, J = 10.6 Hz, 30H), 2.02 
(s, 20H), 1.90 – 1.81 (m, 30H), 1.48 (s, 30H), 1.30 – 1.23 (m, 280H), 0.86 (ddd, J = 8.7, 
8.1, 3.8 Hz, 30H).  13C NMR (101 MHz, CDCl3) δ 170.8, 170.6, 170.1, 168.7, 163.0, 156.7, 
152.7, 135.1, 130.1, 83.7, 83.3, 79.4, 75.3, 68.9, 67.9, 67.7, 62.4, 52.9, 50.2, 49.8, 38.8, 
36.1, 34.6, 34.5, 31.6, 30.13, 29.0, 28.7, 28.3, 28.0, 26.9, 26.0, 25.6, 25.3, 23.0, 22.6, 
21.2, 21.0, 20.8, 20.7, 18.7, 14.1, 11.4. 
25:1 (Ratio) 
1H NMR (400 MHz, CDCl3) δ 11.30 (s, 25H), 8.38 (d, J = 6.2 Hz, 24H), 7.58 (d, J = 30.4 
Hz, 22H), 6.10 (s, 25H), 5.31 (t, J = 11.0 Hz, 100H), 4.32 (d, J = 11.1 Hz, 100H), 4.18 – 
3.92 (m, 100H), 3.85 – 3.76 (m, 100H), 2.90 – 2.65 (m, 75H), 2.53 (d, J = 5.9 Hz, 50H), 
2.15 (s, 75H), 2.13 (s, 75H), 2.02 (s, 100H), 1.83 (s, 125H), 1.54 – 1.23 (m, 425H).  13C 
NMR (101 MHz, CDCl3) δ 170.9, 170.7, 170.1, 168.6, 162.3, 156.5, 152.6, 84.1, 83.3, 79.9, 
75.2, 68.8, 67.7, 62.3, 52.9, 50.3, 49.9, 45.6, 38.8, 30.1, 29.1, 28.7, 28.2, 28.0, 26.0, 
23.0, 21.2, 21.0, 20.9, 8.5. 
 
General Procedures for Deprotection 
144 
 
 
To a stirring solution of appropriate polymer in THF (0.5 mL) lithium hydroxide (10.0 
mg, 3 mL MeOH:H2O 3:1) was added.  The reaction was allowed to stir for 5 hrs, 
neutralized with +H resin.  The resin was filtered out, solvent was removed via vacuo 
and residue was re-dissolved in DCM and TFA (1.0 mL, 1:1 ratio) and allowed to stir for 
1 hr.  Solvent was removed in vacuo and redissolved in H2O and lipolyze overnight to 
give a dark pale foamy solid (70-90% yield). 
SA 
1H NMR (400 MHz, D2O) δ 7.79 (s, 1H), 6.11 (dd, J = 7.9, 2.9 Hz, 1H), 4.33 (dd, J = 17.9, 
11.0 Hz, 1H), 4.06 (t, J = 10.8 Hz, 1H), 3.81 – 3.65 (m, 3H), 3.55 (dd, J = 12.4, 6.7 Hz, 
2H), 3.29 (td, J = 12.1, 4.4 Hz, 1H), 2.81 (dd, J = 13.2, 4.4 Hz, 3H), 2.71 – 2.46 (m, 3H), 
2.12 (dd, J = 9.6, 4.9 Hz, 1H), 1.96 (s, 3H), 1.92 – 1.74 (m, 4H), 1.70 – 1.58 (m, 1H), 1.48 
(dt, J = 14.4, 7.3 Hz, 3H), 1.39 (d, J = 8.5 Hz, 2H), 1.34 – 1.19 (m, 5H), 1.15 (dd, J = 15.4, 
7.4 Hz, 3H).  13C NMR (101 MHz, D2O) δ 175.1, 138.3, 136.2, 123.7, 109.8, 74.6, 71.8, 67.7, 62.4, 
51.5, 50.4, 47.5, 46.5, 45.9, 43.9, 41.3, 34.5, 30.1, 29.0, 25.0, 22.1, 18.8. HRMS (ESI) 
Calculated for C28H44N6O8S 624.2941, found:  625.3017 (M+1). 
 
SG 
1H NMR (400 MHz, D2O) δ 7.80 (s, 1H), 6.11 (dd, J = 7.9, 2.9 Hz, 1H), 4.35 (d, J = 21.1 
Hz, 1H), 3.91 (d, J = 10.5 Hz, 1H), 3.73 (dt, J = 18.6, 6.3 Hz, 3H), 3.59 – 3.46 (m, 4H), 
2.93 – 2.90 (m, 1H), 2.84 (d, J = 5.1 Hz, 2H), 2.74 – 2.61 (m, 2H), 2.60 – 2.45 (m, 1H), 
2.12 (dd, J = 9.7, 4.8 Hz, 1H), 1.91 (s, 3H), 1.85 – 1.75 (m, 3H), 1.69 – 1.60 (m, 1H), 1.54 
– 1.36 (m, 4H), 1.32 – 1.20 (m, 5H), 1.15 (dd, J = 16.0, 6.9 Hz, 3H).  13C NMR (101 MHz, 
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D2O) δ 175.1, 138.3, 136.2, 123.7, 109.8, 74.6, 71.8, 67.7, 62.4, 51.5, 50.4, 47.5, 46.5, 45.9, 43.9, 
41.3, 34.5, 30.1, 29.0, 25.0, 22.1, 18.8.  HRMS (ESI) Calculated for C28H44N6O8S 666.3159, 
found:  667.3232 (M+1). 
SA-25 NH2 Polymer 25:1 
1H NMR (400 MHz, D2O) δ 7.93 (d, J = 162.0 Hz, 8H), 4.13 (s, 22H), 3.93 – 3.65 (m, 
64H), 3.62 – 3.26 (m, 56H), 2.94 – 2.39 (m, 75H), 1.96 (s, 75H), 1.72 (s, 4H), 1.55 – 0.72 
(m, 15H). 
SA-10 
1H NMR (400 MHz, D2O) δ 8.13 (s, 1H), 7.72 (s, 8H), 4.13 (s, 23H), 3.86 – 3.46 (m, 106H), 2.85 
(s, 21H), 2.59 (d, J = 47.4 Hz, 38H), 1.96 (s, 71H), 1.72 (s, 32H), 1.54 – 1.27 (m, 50H), 1.18 (dd, J 
= 14.3, 6.8 Hz, 77H). 
SA-5 
1H NMR (400 MHz, D2O) δ 7.68 (s, 1H), 4.10 (s, 6H), 3.61 (dt, J = 96.0, 45.8 Hz, 42H), 2.83 – 
2.44 (m, 19H), 1.93 (s, 38H), 1.71 (s, 13H), 1.46 – 0.89 (m, 42H). 
SG-25 NHC=NHNH2 Polymer 25:1 
1H NMR (400 MHz, D2O) δ 6.97 (s, 1H), 4.09 (s, 18H), 3.68 (dd, J = 51.7, 30.9 Hz, 55H), 3.30 (s, 
9H), 2.65 (d, J = 127.4 Hz, 22H), 1.93 (s, 41H), 1.69 (s, 23H), 1.40 (s, 18H), 1.13 (s, 89H).  
SG-10 
1H NMR (400 MHz, D2O) δ 7.73 (s, 1H), 7.00 (s, 1H), 5.28 (s, 1H), 3.65 (d, J = 53.2 Hz, 9H), 
2.60 (s, 4H), 2.22 (d, J = 22.6 Hz, 2H), 1.87 (s, 6H), 1.41 (s, 1H), 1.17 (s, 5H).  
SG-5 
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1H NMR (400 MHz, D2O) δ 7.86 – 7.53 (m, 1H), 7.04 (s, 3H), 4.28 (s, 4H), 4.12 (s, 16H), 3.74 – 
3.40 (m, 40H), 2.62 (dd, J = 87.1, 81.1 Hz, 15H), 2.25 (d, J = 20.5 Hz, 20H), 2.02 – 1.60 (m, 
53H), 1.46 – 0.95 (m, 60H). 
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